Clinical Trials on Alzheimer's Disease

Preliminary Program

PALAU DE CONGRESOS DE CATALUNYA
Barcelona, October 24-27, 2018

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17

www.ctad-alzheimer.com
Organizing and Scientific Committees .......................................................... p. 3
Keynote Speakers ........................................................................................................ p. 4
Lifetime Achievement Award .................................................................................. p. 6
Program at a glance ........................................................................................................ p. 7
  – Wednesday, October 24 .................................................................................. p. 9
  – Thursday, October 25 ..................................................................................... p. 10
  – Friday, October 26 ............................................................................................ p. 14
  – Saturday, October 27 ....................................................................................... p. 18
Poster presentations ........................................................................................................ p. 21
Theme 1. Clinical trials: Methodology .................................................................. p. 22-24
Theme 2. Clinical trials: Results .............................................................................. p. 25-27
Theme 3. Clinical trials: Imaging ............................................................................. p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma .......................................... p. 30-34
Theme 7. Behavioral disorders and clinical trials .................................................... p. 43
Theme 8. Health economics and clinical trials ....................................................... p. 44
Theme 9. Epidemiology and clinical trials .............................................................. p. 45-46
Theme 11. New therapies and clinical trials ............................................................ p. 48-49
Our sponsors ................................................................................................................. p. 50
Registration / Accommodations ............................................................................... p. 51
CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer’s
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Steven DEKOSKY (Miami)
Rachelle DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (Vancouver)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)

Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesota)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Rachel SCHINDLER (New York)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)
«Blood biomarkers for AD clinical trials»

Randall Bateman, MD, PhD

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer’s disease. Dr. Bateman’s laboratory investigates the causes and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer’s disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer’s Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.

«What have we learned from Aducanumab?»

Samantha Budd Haeberlein, PhD

Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer’s Disease Discovery & Development. Dr. Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr. Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women’s Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.

«Anti-Tau Treatments: Potential, Challenges, and Progress»

Lennart Mucke, MD

Dr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Dr. Mucke’s research focuses on mechanisms that result in functional deficits in Alzheimer’s disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Mucke has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer’s Association and on the National Advisory Council on Aging for the NIH.
«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD
Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor Joao Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008−2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010−2014.

«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD
Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Sciences, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.
2018 Recipient of the CTAD Lifetime Achievement Award

Rachelle Doody MD, PhD

Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and its US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.
Wednesday, October 24

4.00 - 4.30 p.m. Opening Ceremony and CTAD Lifetime Achievement Award

4.30 - 5.00 p.m. Keynote 1 - Blood biomarkers for AD clinical trials

5.00 - 5.50 p.m. Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease

5.50 - 6.40 p.m. Emerging Results From Other BACE Inhibitor Trials

6.40 - 7.00 p.m. Late breaking oral communication

Thursday, October 25

8.30 - 10.00 a.m. Oral communications

10.00 - 10.30 a.m. Coffee break and poster session

10.30 - 11.30 a.m. Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

11.30 - 12.30 p.m. Oral communications

12.30 - 1.30 p.m. Lunch and poster session

1.30 - 2.00 p.m. Keynote 2 - What have we learned from Aducanumab?

2.00 - 2.30 p.m. Late breaking oral communications

2.30 - 3.30 p.m. Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

3.30 - 4.30 p.m. Oral communications

4.30 - 5.00 p.m. Coffee break and poster session

5.00 - 6.00 p.m. Symposium 4 - Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.
Friday, October 26

8.30 - 10.00 a.m. Oral communications

10.00 - 10.30 a.m. Coffee break and poster session

10.30 - 11.00 a.m. Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress

11.00 - 11.30 a.m. Late Breaking communications

11.30 - 12.30 p.m. Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)

12.30 - 1.30 p.m. Lunch and poster session

1.30 - 2.45 p.m. Oral communications

2.45 - 4.00 p.m. Late Breaking communications

4.00 - 4.30 p.m. Coffee break and poster session

4.30 - 5.00 p.m. Keynote 4 - Combination therapy in AD

5.00 - 6.00 p.m. Symposium 6 - Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance

Saturday, October 27

8.30 - 9.15 a.m. Presentation and panel discussion: AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results

9.15 - 9.45 a.m. Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research

9.45 - 10.15 a.m. Coffee break and poster session

10.15 - 11.15 a.m. Oral communications

11.15 - 12.15 p.m. Symposium 7 - Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults

12.15 - 1.15 p.m. Lunch and poster session

1.15 - 3.45 p.m. Oral communications

3.45 p.m. End of conference
Wednesday, October 24

4.00 - 4.30 p.m.  
Opening Ceremony and CTAD Lifetime Achievement Award  
Jacques Touchon, Paul Aisen, Bruno Vellas, Milte Weiner, Merce Boada, Jose Luis Molinuevo. The recipient of this year’s CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials.

4.30 - 5.00 p.m.  
Keynote 1  
Blood biomarkers for AD clinical trials  
Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA.

5.00 - 5.50 p.m.  
Symposium 1  
APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease  
Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA  
Communication 1: Results from the APECS trial  
Michael F. Egan, MD, MD1, Tiffini Voss, MD, MD1, Yuhi Mukai, MD, MD1, James Kost, Ph.D, MD1, Paul S Aisen, MD, MD1, Jeffrey L. Cummings, MD, ScD1, Pierre N. Tariot, MD, MD1, Bruno Vellas, MD, Ph.D, MD1, Christopher H. van Dych, MD, MD1, Ying Zhang, Ph.D, MD1, Wen Li, Ph.D, MD1, Christine Furtel, BS, BA1, Lyn Harper Mozley, Ph.D, MD1, Yi Mo, Ph.D, MD1, Cyrille Sur, Ph.D, David Michelson, MD1  
1Merck & Co., Inc., Kenilworth, NJ, USA 2University of Southern California, San Diego, CA, USA 3Cleveland Clinic, Las Vegas, NV, USA 4Banner Alzheimer's Institute, Phoenix, AZ, USA 5Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France 6Yale University School of Medicine, New Haven, CT, USA.

Communication 2: Panel discussion  
Paul S. Aisen, MD, MD1, Maria C. Carrillo, PhD1, Pierre N. Tariot, MD, MD1, Bruno Vellas, MD, PhD1  
1University of Southern California, San Diego, CA, USA 2The Alzheimer Association, Chicago, IL, USA 3Banner Alzheimer's Institute, Phoenix, AZ, USA 4Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

5.50 - 6.40 p.m.  
Emerging Results From Other BACE Inhibitor Trials  
Discussion of BACEi Trial Findings: Challenges and Opportunities  
CoChairs: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association  
Presentation 1: Preliminary analyses of data from an ongoing trial of atabecestat in preclinical Alzheimer’s disease.  
Gary Romano, MD, PhD Janssen R&D, USA  
Presentation 2: LBI - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer’s disease dementia.  
Albert C Lo1, Cynthia Duggan Evans1, Michele Mancini1, Qun Lin, Hong Wang1, Peng Liu1, Sergey Shcherbinin1, Ming Lu1, Arnaud Charil1, Brian A Willis1, Michael Irizarry1  
1Eli Lilly and Company, Indianapolis, IN, USA 2Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ  
Panel discussion: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association, Mark Mintun, MD, Eli Lilly & Co., Michael Egan, MD, Merch & Co., Gary Romano, MD, PhD Janssen R&D, Ana Graf, MD, Novartis & Amgen, Inc., Johan Luthman, MD, Eisai Co., Ltd., John Sims, MD, Lilly/AZ Alliance

6.40 - 7.00 p.m.  
Late Breaking Oral communication  
LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results  
Robert Alexander, MD1, Daniel K. Burns, PhD2, Kathleen A. Welsh-Bohmer, PhD3, Carl Chiang, PhD3, Meredith Culp, BS3, Janet O’Neill, MBA4, Brenda L. Plassman, PhD4, Craig Metz, PhD4, Deborah Yarbrough, MS, MBA4, Jingtao Wu, PhD4, Rebecca Evans, MD4, Kumar Budur, MD4, Stephen K. Brannan, MD4, Ann M. Saunders, Ph.D4, Emiliano Ratti, PhD5  
1Takeda Development Center Americas, Inc., Cambridge, MA, USA 2Zinfandel Pharmaceuticals, Inc., Durham, NC, USA 3Duke University Bryan ADRRC, Durham, NC, USA 4Takeda Development Center Americas, Inc, Deerfield, IL, USA 5Takeda Development Center Americas, Inc.
Oral communications

8.30 - 8.45 a.m.  OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer's dementia
Christopher H. van Dyck, MD,1 Haakon B. Nygaard, MD, PhD,2 Kewei Chen, PhD,3 Michael C. Donohue, PhD,4 Rema Raman, PhD,5 Robert A. Rissman, PhD,6 James B. Brewer, MD, PhD,7 Robert A. Koeppe, PhD,8 Tiffany W. Chow, MD,9 Michael S. Rafii, MD,9 R. Scott Turner, MD, PhD,9 Jeffrey A. Kaye, MD,9 Seth A. Gale, MD,9 Eric M. Reiman, MD,1 Paul S. Aisen, MD,1 Stephen M. Strittmatter, MD, PhD1

1Yale University School of Medicine, New Haven, USA 2The University of British Columbia, Vancouver, Canada 3Banner Alzheimer's Institute, Phoenix, USA 4Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA 5University of California San Diego, La Jolla, USA 6University of Michigan, Ann Arbor, USA 7Georgetown University, Washington, DC, USA 8Oregon Health & Science University, Portland, USA 9Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.  OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics
Suzanne Craft, PhD,1 Rema Raman, PhD,2 Tiffany Chow, MD,2 Michael S Rafii, MD,2 Robert A. Rissman, PhD,3 James B. Brewer, MD, Michael Donohue, PhD,2 Chung-Kai Sun, MS,9 Kelly Harless,9 Devon Gessert,9 Paul S. Aisen, MD8

1Wake Forest School of Medicine, Winston-Salem, USA, 2University of Southern California, Los Angeles, USA, 3University of California, San Diego, USA

9.00 - 9.15 a.m.  OC3 - Phase 3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China
Shifu Xiao, MD,1 Zhenxin Zhang, MD,2 Meiyu Geng, PhD,3 GV-971 Study Group

1Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China 2Peking Union Medical College Hospital, Beijing, China 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m.  OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study
Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team

United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m.  OC5 - Elenbecestat in MCI-to-moderate Alzheimer’s disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints
Shau Yu Lynch, PhD,1 June Kaplow, PhD,2 Jim Zhao, MS, MM,3 Shobha Dhadda, PhD,4 Johan Luthman, PhD, DDS,5 Bruce Albaia, PhD6

1Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m.  OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer’s disease: Phase Ib/2a outcomes update
Roberta D. Brinton, PhD,1 Gerson D. Hernandez, MD, MPH,1 Naoko Kono, MPH,1 Claudia M. Lopez, BS,1 Christine Solomon, PhD,1 Kathleen Rodgers, PhD,1 Jin Gahm, PhD,1 Dogu Aydogan, PhD,1 Yonggang Shi, PhD,1 Sonia Pawluczycz, MD,1 Meng Law, MD,1 Wendy Mach, PhD,1 Lon Schneider, MD, MM1

1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA 2Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA 4USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA 6Department of Radiology, University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m.  Coffee break and poster session
Symposium 2
Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers?
Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.
Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.
Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc., NJ, USA

Oral communications

11.30 - 11.45 a.m. OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study
Gil D. Rabinovici,1 Constantine Gatsonis,2 Charles Apgar,3 Kiran Chaudhary,4 Ilana Careen,2 Lucy Hanna,2 James Hendrix,5 Bruce E. Hillner,2 Cynthia Olson,1 Orit Lesman-Segev,1 Justin Romanoff,1 Barry A. Siegel,1 Rachel A. Whitmer,1 Maria C. Carrillo,1 on behalf of the IDEAS investigators.
1Department of Neurology, University of California San Francisco, 2Center for Statistical Sciences, Brown University, 3American College of Radiology, 4Alzheimer’s Association, 5Department of Medicine, Virginia Commonwealth University, 6Department of Radiology, Washington University, 7Division of Research, Kaiser Permanente

11.45 - 12.00 p.m. OC8 - Safety and efficacy of estrogen receptor-β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase Ib/2a trial outcomes
Lon S. Schneider, MD1, Gerson Hernandez MD MPH2, Liqin Zhao PhD3, Sonia Pawluczyk MD, Wendy J. Mack, PhD4, Roberta D. Brinton PhD5
1Keck School of Medicine of the University of Southern California, Los Angeles, USA, 2University of Arizona, Center for Innovation in Brain Science, Tucson, USA, 3University of Kansas, USA

12.00 - 12.15 p.m. OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD
Huntington Potter, PhD Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels
Rocky Mountain Alzheimer’s Disease Center, Department of Neurology, University of Colorado School of Medicine

12.15 - 12.30 p.m. OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer’s disease
David Allsop PhD1,2, Anthony Aggidis MSc1, Nigel Fullwood PhD1, Mark Taylor PhD2, Penny Foulds PhD1,2, Shoona Vincent PhD2, Mark Dale MD2
1Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, 2Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

12.30 - 1.30 p.m. Lunch and poster session

1.30 - 2.00 p.m. Keynote 2
What have we learned from Aducanumab?
Samantha Budd Haeberlein, PhD - Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA
2.00 - 2.30 p.m. Late Breaking Oral communications

LB3 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease
Bjørn Sperling, MD¹, Lars Østergaard Pedersen, PhD¹, Neli Boneva, MD³, Dorte Daugaard, MD³, Yudong Zhao, PhD¹
¹H. Lundbeck A/S, Valby, Denmark

2.15 - 2.30 p.m. LB4 - Predictors of [18F]flortaucipir (tau) load in Alzheimer’s disease and other neurodegenerative disorders
Oskar Hansson, MD, PhD², Gil D. Rabinovici MD, PhD³, Chul H. Lyoo, MD, PhD⁴ & Rik Ossenkoppele, PhD⁵
¹Lund University, Clinical Memory Research Unit, Lund, Sweden, ²Memory Clinic, Ståhlne University Hospital, Malmö, Sweden, ³Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, ⁴Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁵VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

2.30 - 3.30 p.m. Symposium 3
Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD
Eisai Inc, Woodcliff Lake, NJ, USA

3.30 - 4.30 p.m. Oral communications

OC11 - Safety and efficacy of lemborexant for sleep-wake regulation in patients with irregular sleep wake rhythm disorder and Alzheimer’s disease dementia
Margaret Moline, PhD¹, Mohammad Bsharat, PhD¹, Manuel Kemethofer, MSc², Gleb Filippov, MD, PhD³, Naoki Kubota, MPHarm³, Patricia Murphy, PhD¹
¹Eisai, Inc., Woodcliff Lake, USA, ²The Siesta Group, Vienna, Austria, ³Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m. OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies
Adam S Fischler¹, Michael J Pontecorvo¹, Michael D Devous¹, Ming Lu¹, Sergey Shcherbinin¹, Anupa K Arora¹, Mark A Minun²
¹Eli Lilly & Co, Indianapolis, IN, USA, ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00 - 4.15 p.m. OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer’s disease
Cyrille Sur, Ph.D¹, James Kost, Ph.D¹, David Scott, Ph.D², Katarzyna Adamczuk, Ph.D², Nick C Fox, Ph.D¹, Jeffrey Cummings, MD, ScD³, Pierre Tariot, MD³, Paul Aisen, MD³, Bruno Vellas, MD, Ph.D³, Tiffrini Voss, MD³, Yuki Mukai, MD¹, David Michelson, MD¹, Michael Egan, MD¹
¹Merck & Co., Inc., Kenilworth, NJ, USA, ²Bioclinica, Newark, CA, USA, ³University College London, London, UK, ⁴Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ⁵BonnerAlzheimer’s Institute, Phoenix, AZ, USA, ⁶University of California San Diego, San Diego, CA, USA, ⁷Gerontopole, Toulouse University Hospital, Toulouse, France

4.15 - 4.30 p.m. OC14 - Distinct Tau PET Patterns in Atrophy-Defined Subtypes of Alzheimer’s disease
Rik Ossenkoppele, Ph.D¹², Gil D. Rabinovici, M.D.¹, Chul H. Lyoo, M.D., Ph.D.² & Oskar Hansson, M.D., Ph.D.⁵
¹Lund University, Clinical Memory Research Unit, Lund, Sweden, ²VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, ³Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, ⁴Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁵Memory Clinic, Ståhlne University Hospital, Malmö, Sweden

4.30 - 5.00 p.m. Coffee break and poster session
Symposium 4
Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.

Moderator: Pedro Pesini PhD. Araclon Biotech-Grifols, Spain.

Communication 1: Developing Aβ blood based test into pre-screening tools for clinical trials in early stages of AD
Victor L. Villemagne, M.D. Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

Communication 2: Plasma ratio of total Aβ42 to total Aβ40 in amnestic MCI patients is associated with FDG-PET, amyloid-PET, CSF and the risk of progression to AD dementia.
Anne Fagan PhD, Washington University, Saint Louis, Missouri.

Communication 3: Total Aβ42 to total Aβ40 as a biomarker of cortical amyloid burden in subjects with subjective memory complaints.
Agustín Ruiz MD PhD. Research Director, Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Oral communications

8.30 - 8.45 a.m.  
OC15 - Cocoa supplement and multivitamin outcomes study of cognitive function (cosmos-mind): design of a large randomized clinical trial  
Laura D. Baker, PhD1, Mark A. Espeland, PhD1, Stephen R. Rapp, PhD1, Sally A. Shumaker, PhD1, Sarah A. Gaussoin, MS1, Howard D. Sesso, ScD1, JoAnn E. Manson, MD, DrPH2  
1Wake Forest School of Medicine, Winston-Salem, USA, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.  
OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer’s disease  
Jonas Hannestad, MD PhD1, Ian Gallager, PhD1, Katie Koborsi, MS1, S. Sakura Minami, PhD1, Darby Stephens, MBA1, Vittoria Kheifets, PhD1, Steven Braithwaite, PhD1  
1Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m.  
OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer’s disease patients in general population  
Olga Uspenskaya-Cadoz1, Chaitanya Alamuri2, Sam Khinda1, Yuliya Nigmatullina3, Carolina Rubel3, Lanhui Wang1, Mengting Yang2, Tao Cao2, Nikhil Kaya12  
1IQVIA CNS Center of Excellence, 2IQVIA Analytics Center of Excellence, 3IQVIA Project Leadership

9.15 - 9.30 a.m.  
OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer’s disease: Updated design and baseline characteristics of phase 2 study  
Hana Florian, MD1, Steven E. Arnold, MD2, Randall J. Bateman, MD2, Joel B. Braunstein, MD, MBA2, Kumar Budur, MD1, Diana R. Kerwin, MD3, Holly Soares, PhD1, Delli Wang, PhD1, David M. Holtzman, MD3  
1AbbVie, Inc., North Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Washington University, St. Louis, MO, USA

9.30 - 9.45 a.m.  
OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in real life (IMAP) study  
A. Graf1, V. Risson1, S. Tziveleth2, A. Gustavsson1, V. Bezlyak1, A. Caputol1, P.N. Tariot4, J.B. Langbaum1, C. Lopez Lopez1, V. Viglietta2  
1Novartis Pharma AG, 2Amgen, Inc., 3Quantify Research, 4Banner Alzheimer’s Institute

9.45 - 10.00 a.m.  
OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer’s disease to four large study cohorts.  
Roos J. Jutten, MSc1, Rebecca E. Amargillo, PhD23, Gad A. Marshall, MD, PhD23, Dorene M. Rentz, PhD23, Wiesje M. Van der Flier, PhD2, Philip Scheltens, MD, PhD1, Keith A. Johnson24, Reisa A. Sperling, MD23, PhD, Sietske A.M. Sijlteses, PhD1, Kathryn V. Papp, PhD23  
1Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, 2Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, 3Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

10.00 - 10.30 a.m.  
Coffee break and poster session

10.30 - 11.00 a.m.  
Keynote 3  
Anti-Tau treatments: Potential, challenges, and progress  
Lennart Mucke, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA
Late Breaking communications

**LB5 - 18F-AV-1451-A16: A clinicopathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology**

Mark A. Mintun\(^1\), Adam S. Fleisher\(^2\), Michael D. Devous\(^3\), Ming Lu\(^4\), Anupa K. Arora\(^2\), Thomas G. Beach\(^4\), Thomas J. Montine\(^5\), Michael J. Pontecorvo\(^6\)

\(^{1}\)Eli Lilly and Company, Indianapolis, IN, USA; \(^{2}\)Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA; \(^{3}\)Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA; \(^{4}\)Department of Pathology, Stanford University, Stanford, CA, USA

**Symposium 5**

Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)

**Moderator:** Rachelle Doody, MD, PhD\(^1,2\)

\(^{1}\)Genentech, Inc., South San Francisco, CA, USA; \(^{2}\)F. Hoffmann-La Roche Ltd, Basel, Switzerland

**Communication 1:** Self-detection of cognitive problems: benefits and challenges of online and digital tools

Mary Sano, PhD\(^1\)

\(^{1}\)Director, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, \(^{2}\)Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

**Communication 2:** Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers

Christopher van Dyck, MD\(^1,4\)

\(^{1}\)Alzheimer’s Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA; \(^{2}\)Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; \(^{3}\)Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA; \(^{4}\)Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

**Communication 3:** Moving towards combination therapies for disease modification in AD

Dennis J. Selho, MD\(^2\)

\(^{1}\)Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, USA; \(^{2}\)Harvard Medical School, Boston, MA, USA

Lunch and poster session

Oral communications

**OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures**

Lyduine Collij, MSc\(^{1}\), Fiona Heeman, MSc\(^{1}\), Gemma Salvadó Blasco, MSc\(^{2}\), Elles Konijnenberg, MD, MSc\(^{3}\), Anoult den Braber, PhD\(^{4}\), Maqsood Yaqub, PhD\(^{5}\), Pieter Jelle Visser, MD, PhD\(^{3}\), Alie Meije Winb, Ir, PhD\(^{3}\), Philip Scheltens, MD, PhD\(^{3}\), Ronald Boellaard, PhD\(^{1}\), Bart N.M. van Berckel, MD, PhD\(^{3}\), Juan Domingo Gispert López, PhD\(^{3}\), Mark Schmidt, MD, PhD\(^{5}\), Frederik Barkhof, MD, PhD\(^{1,6}\), Isadora Lopes Alves, PhD\(^{1}\)

\(^{1}\)Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; \(^{2}\)BarcelonaBeta Brain Research Center, Barcelona, Spain; \(^{3}\)Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands; \(^{4}\)Dept. of Biological Psychology, VU University Amsterdam, The Netherlands; \(^{5}\)Janssen Pharmaceutica; Beerse, Belgium; \(^{6}\)Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom

**OC22 - Twenty-four-month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies**

Gregory Klein, PhD\(^{1}\), Paul Delmar, PhD\(^{2}\), Carsten Hofmann, PhD\(^{3}\), Danielle Abi-Saab, PsyD\(^{4}\), Mirjana Andjelkovic, PhD\(^{5}\), Smiljana Ristic, MD\(^{6}\), Nicola Voyle, PhD\(^{3}\), Jacob Hesterman, PhD\(^{3}\), John Seibyl\(^{1}\), Ken Marek\(^{5}\), Ferenc Martenyi, MD\(^{2}\), Monika Baudler, PhD\(^{2}\), Paulo Fontoura, MD, PhD\(^{2}\), Rachelle Doody, MD, PhD\(^{2}\)

\(^{1}\)Roche Pharma Research and Early Development, Basel, Switzerland; \(^{2}\)Roche / Genentech Product Development, Neuroscience, Basel, Switzerland; \(^{3}\)Roche Products Ltd, Welwyn Garden City, UK; \(^{4}\)InvCRO, LLC, Boston, MA, USA
2.00 - 2.15 p.m. **OC23** - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS
Mia Kivipelto1,2,3, On behalf of the World-Wide FINGERS network
1Karolinska Institute, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden, 2University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland, 3Imperial College London, NEA, School of Public Health, UK

2.15 - 2.30 p.m. **OC24** - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials
Christian Dansereau1, PhD, Maor Zaltzhendler1, MEng, Angela Tam2,3, MSc, Pedro Rosa-Neto1, MD, PhD, Serge Gauthier1, MD, Pierre Bellec2,4, PhD
1Perceiv Research Inc., Montreal, CAN, 2Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal, CAN, 3Douglas Mental Health University Institute, McGill University, CAN, 4Department of Computer Science and Operations Research, University of Montreal, CAN

2.30 - 2.45 p.m. **OC25** - Study update on XanADu: Phase II study of Xanamem™ in subjects with mild dementia due to Alzheimer’s disease
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

2.45 - 4.00 p.m. Late Breaking communications

2.45 - 3.00 p.m. **LB6** - Age and ApoE genotype-specific population frequencies of cerebral β-amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO
Hany Rofael, MD, PhD1, Gerald Novak MD1, Luc Bracoud MSc2, Nandini Raghavan PhD1, Iiad Saad PhD1, S Einstein MS, Robert Brashhear1, David Scott PhD2, Joel Schaerer PhD2, Celeste de Jager PhD2, Chi Udeh-Momoh, PhD2, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and Leftkos Middleton MD5

3.00 - 3.15 p.m. **LB7** - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer’s disease
Marwan Sabbagh, MD1, Imogene Dunn, PhD2, Ann Gooch, PhD2, Tom Soeder, MS3, Karl Kieburtz, MD, MPH4, Carmen Valcarce, PhD2, Larry D Alstiel, MD, PhD2, Aaron H Burstein, PharmD2
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 2vTv Therapeutics LLC, High Point, NC, USA, 3Cato Research LTD, Durham, NC, USA, 4Climtrex LLC, Longboat Key, FL, USA

3.15 - 3.30 p.m. **LB8** - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer’s disease
Samantha Budd Haeberlein, PhD1, Carmen Castrillo-Viguera, MD, PhD1, Tianle Chen, PhD1, John O’Gorman, PhD1, Raj Rajagovindan, PhD1, Dalshhaben Patel, PhD1, Philipp von Rosenstiel, MD1, Guanfang Wang, PhD1, Spyros Chalkias, MD1, LeAnne Shortos PharmD1, Claudia Prada, MD1, Christoph Hoch, MD1, Roger M Nitsch, MD1, Alfred Sandrock, MD, PhD1
1Biogen, Cambridge, MA, USA, 2Biogen, Maidenhead, UK, 3Cybel, Cambridge, MA, USA, 4Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

3.30 - 3.45 p.m. **LB9** - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1, Mohammad Afshar, MD, PhD2, Frédéric Parmentier, PhD2, Coralie Williams, MSc2, Adrien Etcheto, MSc2, Federico Goodsaid, PhD3, Christopher U Missling, PhD4
1Department of Neurology, Sorbonne University, Paris, France, 2Ariana Pharma, Paris, France, 3Regulatory Pathfinders LLC, San Francisco, CA, 4Anavex Life Sciences Corp, New York, NY

3.45 - 4.00 p.m. **LB10** - Predictive performance of CSF and imaging AD biomarkers in ADNI1/GO/2 MCI participants using the NIA-AA research framework
Leslie M Shaw, PhD1, Michal Figurski, PhD1, Susan Landau, PhD2, William J jugst, MD2, Clifford R Jack, MD2, Paul S Aisen, MD1, Ronald C Petersen, MD, PhD1, Michael W Weiner, MD2, John Q Trojanowiski, MD, PhD1
1University of Pennsylvania, Philadelphia, USA, 2University of California, Berkeley, Berkeley, USA, 3Mayo Clinic, Rochester, USA, 4University of Southern California, San Diego, USA, 5University of California, San Francisco, San Francisco, USA
Coffee break and poster session

4.30 - 5.00 p.m.

Keynote 4
Combination therapy in AD
Daniel M. Shovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m.

Symposium 6
Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance
Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA

Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease
Reisa Sperling, MD1, Ronald C. Petersen, MD, PhD2, Gary Romano, MD, PhD3, Paul Maruff, PhD4
1Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA, 2Department of Neurology, Mayo Clinic, Rochester, MN, USA, 3Janssen R&D, Titusville, NJ, USA, 4Cogstate Ltd, Melbourne, Victoria, Australia

Communication 2: Biomarkers in Stage 1, 2 and 3 Disease
Samantha Budd Haeberlein PhD1, Jose Luis Molinuevo, MD, PhD2, Christopher C. Rowe, PhD3, Maria C. Carrillo PhD4, Clifford R. Jack, Jr., MD5
1Biogen, Cambridge, MA, USA, 2BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-DIBAPS, Barcelona, Spain, 3Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, 4Alzheimer’s Association, Chicago, IL, USA, 5Department of Radiology, Mayo Clinic, Rochester, MN, USA

Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects
Chris J. Edgar, PhD1, George Vradenburg, JD2, Jason Hassenstab, PhD3
1Cogstate Ltd, London, UK, 2UsAgainstAlzheimer’s and Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, 3Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
8.30 - 9.15 a.m.

Presentation and panel discussion:
**AMBAR (Alzheimer’s Management By Albumin Replacement)**
**Phase IIb/III Results**

Presentation by Antonio Páez MD, Grifols S.A., Barcelona, Spain

Followed by Panel Discussion with:

Panel discussion moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA
- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m.

Keynote 5
**How BIG and GOOD Data are revolutionizing neurodegenerative disease research**

Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA

9.45 - 10.15 a.m.

Coffee break and poster session

10.15 - 11.15 a.m.

Oral communications

10.15 - 10.30 a.m.

**OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials**

Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Mira Chamoun PhD, Joseph Therriault BSc, Robert Hopewell PhD, Gassan Massarweh PhD, Andrea L. Benedet, MSc, BSc, Min Su Kang, Jean-Paul Soucy MD, Serge Gauthier, MD, Pedro Rosa-Neto, MD, PhD

1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada,
2Montreal Neurological Institute, McGill University, Montreal, Canada

10.30 - 10.45 a.m.

**OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer’s disease in AIBL**

Samantha C. Burnham, Preciosa M Coloma, Qiao-Xing Li, Steven Collins, Greg Savage, Simon Laws, James Doechte, Paul Maruff, Ralph N Martins, David Ames, Christopher C Rowe, Colin L Masters, Victor L Villenmagne

1eHealth, CSIRO, Parkville, VIC, Australia; 2School of Medical Sciences, Edith Cowan University, Joondalup, Australia; 3Product Development PERSONALIZED HEALTH CARE - DATA SCIENCE, F. Hoffmann-La Roche Ltd., Basel, Switzerland; 4The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia; 5Department of Pathology, University of Melbourne, Parkville, Australia; 6Macquarie University, Sydney, Australia; 7eHealth, CSIRO, Herston, QLD, Australia; 8Cogstate Ltd., Melbourne, Australia; 9Macquarie University, North Ryde, Australia; 10National Ageing Research Institute, Melbourne, Australia; 11Austin Health, Melbourne, Australia; 12Brain Health, Las Vegas, NV, USA

10.45 - 11.00 a.m.

**OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis**

Jacques Touchon, MD, PhD, Laura Auboyer, PhD, Johann Meunier, PhD, Laura Ceolin, PhD, François J. Roman, PhD, Rémy Burcelin, PhD, Guillaume J. Blivet, MS

1Montpellier University, France; 2INSERM U1061, Montpellier, France; 3REGENLIFE SAS, Montpellier, France; 4Amylgen SAS, Montfernier-sur-Lez, France; 5Vailomer SAS, Labège, France
Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults

Symposium co-moderators: Athene Lee PhD1,2 and Jessica Alber PhD1,2

Warren Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital, Providence, RI, USA

Communication 1: “Not just a colonoscopy” – cognitively normal older adults reactions to learning an amyloid PET result

Jason Karlawish, MD1,2, Kristin Harkins, MPH2, Emily Largent, JD, PhD3, Pamela Sanhar, PhD1, Jeff Burns, MD4, David Sulzer, MD, PhD5, Joshua Grill, PhD6

1Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA; 2Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA; 3Department of Neurology, University of Kansas, Kansas City, KS, USA; 4Department of Psychiatry, University of California, Los Angeles, CA, USA; 5Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

Communication 2: Remote genetic counseling and disclosure of APOE genotype within the Generation study 1

Elisabeth McCarty Wood, MS1, Cara Cacioppo, MS1, Neeraja Reddy, MS2, Dare Henry-Moss, MPH1, Demetrios Ofidis, BS1, Brian L. Egleston, PhD1, Jason Karlawish, MD1,2, Scott Roberts, PhD1, Scott Kim, MD, PhD1,2, Carolyn Langlois, MA2, Eric M. Reiman, MD, PhD3,4,5, Pierre N. Tariot, MD1,2, Jessica B. Langbaum, PhD2,3,5, Angela R. Bradbury, MD1,2,3,6

1University of Pennsylvania, Philadelphia, PA, USA; 2Mapmygenome, Navi Mumbai, India; 3Fox Chase Cancer Center, Philadelphia, PA, USA; 4University of Michigan, Ann Arbor, MI, USA; 5National Institutes of Health, Bethesda, MD, USA; 6Banner Alzheimer’s Institute, Phoenix, AZ, USA

Communication 3: Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results

Louisa Thompson, PhD1,2, Athene Lee, PhD1,2, Meghan Collier, PhD1,2, Danielle Goldfarb, MD1,2, Britany Dawson, FNP2, Stephen Salloway, MD1,2, Jessica Alber, PhD1,2

Warren Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital, Providence, RI, USA

Lunch and poster session

Oral communications

OC30 - Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus

Robert Vassar, PhD Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation

Gustavo A. Jimenez-Maggiora, MBA1, Rema Raman, PhD1, Michael S. Rafii, MD, PhD1, Reisa Anne Sperling, MD2, Jeffrey Lee Cummings, MD1, Paul S. Aisen, MD3

1Alzheimer’s Therapeutics Research Institute, University of Southern California, San Diego, CA, USA; 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 3Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 4Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
2.15 - 2.30 p.m.  
**OC34** - Development of Aβ, tau and cognitive changes during the time course of sporadic Alzheimer's disease  
Niklas Mattsson, MD, PhD¹, Oskar Hansson, MD, PhD¹, Michael W. Weiner, MD², Philip S. Insel, MS¹,²  
¹Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, ²Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA

2.30 - 2.45 p.m.  
**OC35** - U.S. POINTER: Study design and trial kick-off  
Laura Baker, Ph.D.¹; Mark Espeland, Ph.D.¹; Miia Kivipelto, M.D., Ph.D., Gustavo Jimenez-Maggiora, MBA, Martha Clare Morris, Sc.D., Rema Raman, Ph.D., Scott Rushing, Heather M. Snyder, Ph.D., Jeff Williamson, M.D., Rachel Whitmer, Ph.D., Nancy Woolard ¹  
¹Wake Forest School of Medicine On Behalf of the U.S. POINTER Study Team

2.45 - 3.00 p.m.  
**OC36** - Implications for AD clinical trials and opportunities to leverage the first Alzheimer’s association U.S. National Best Clinical Practice Guidelines for the evaluation of cognitive behavioral syndromes, Alzheimer’s disease and related eamentias  
Alireza Atri, MD/PhD,¹,² Mary Norman, MD,³ David S. Knopman, MD,⁴ Jason Karlawish, MD,⁵ Mary Sano, Ph.D.⁶, Carolyn Cleveenger, DNP,⁷ Chiadi U Onyike, MD, MHS,⁸ Susan Scanland, MSN, CRNP, GNPBC,⁹ Paige Lin, PhD¹⁰, James Hendrix, PhD¹¹, Maria C. Carrillo, Ph.D.¹², Brad C. Dickerson, MD² and Alzheimer’s Association Best Clinical Practices Workgroup  
¹Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, ²Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, ³Erickson Living, Dallas, TX, USA, ⁴Mayo Clinic, Rochester, MN, USA, ⁵University of Pennsylvania, Philadelphia, PA, USA, ⁶James J. Peters VA Medical Center, New York, NY, USA, ⁷Emory University, Atlanta, GA, USA, ⁸Johns Hopkins University, Baltimore, MD, USA, ⁹Dementia Connection, Claris Summit, PA, USA, ¹⁰Tufts Medical Center, Boston, MA, USA, ¹¹Alzheimer’s Association, Chicago, IL, USA, ¹²Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA

3.00 - 3.15 p.m.  
**OC37** - Pros and cons of AD composite endpoints considering recently revised regulatory guidance and 2018 NIA-AA research framework  
Michael T. Ropachki, PhD², Suzanne Hendrix, PhD³  
²Strategic Global Research & Development, Half Moon Bay, USA, ³Pentara Corporation, Salt Lake City, USA

3.15 - 3.30 p.m.  
**OC38** - The European Prevention of Alzheimer’s Dementia (EPAD); Summary of First Formal Data Lock (EPAD V500.0) and predictors of amyloid status  
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh UK

3.45 p.m.  
End of conference
Theme 1. Clinical trials: Methodology
P21, P45, P54, P59, P61, P82, P86, P90, P91-P101 and LBP1 to LBP12

pages 22 - 24

Theme 2. Clinical trials: Results
P7, P12, P13, P15-P18, P36, P80, P109-P112 and LBP13 to LBP21

pages 25 - 27

Theme 3. Clinical trials: Imaging
P10, P35, P62, P76, P113-P124 and LBP21 to LBP24

pages 28 - 29

Theme 4. Clinical trials: Biomarkers including plasma
P1, P4, P22, P28, P30, P39, P44, P57, P64-P66, P73, P78, P81, P125-P130
and LBP25 to LBP40

pages 30 - 34

Theme 5. Clinical trials: Cognitive and functional endpoints
P2-P3, P8-P9, P19, P25-P27, P53, P67, P69, P71, P74, P77, P83, P140-P144,
P146-149 and LBP41 to LBP46

pages 35 - 38

Theme 6. Cognitive assessment and clinical trials
P6, P14, P24, P29, P33-P34, P41-P42, P47-P52, P55, P63, P68, P70, P72,
P75, P87-P89, P151-P159, P162 and LBP47 to LBP52

pages 39 - 42

Theme 7. Behavioral disorders and clinical trials
P32, P37, P43, P163 and LBP53

page 43

Theme 8. Health economics and clinical trials
P17, P40, P58, P164

page 44

Theme 9. Epidemiology and clinical trials
P17, P38, P46, P165-P168 and LBP54 to LBP56

pages 45 - 46

Theme 10. Clinical Trials: Animal Models
P102-P104 and LBP58

page 47

Theme 11. New therapies and clinical trials
P5, P11, P20, P23, P56, P60, P79, P84-P85, P105-P108 and LBP59 to LBP62

pages 48 - 49
Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI
Ryoho Ibara, MD,1 Kazushi Suzuki, MD,2 Atsushi IWata, MD,3 Takeshi Iwatsubo, MD,1,3, the Japanese Alzheimer’s Disease Neuroimaging Initiative
1The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Neurology, The University of Tokyo, Tokyo, Japan, 3Department of Neuropathology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research
Jacobo Mintzer, MD, MBA1, Mike Spline2, Erinn Bech, MPH3
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA; 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of alzheimer’s biomarkers: β-amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform
Sayta Nandana Narla1, Amanda Dider1, Ming Hu1, Tina LV2, Yuan Xueling3 and Martine Florent4
1Immunology Department, Covance Central Laboratories, Indianapolis, USA; 2Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD1, Marco Canevelli, MD, PhD1, Giuseppe Bruno, MD1, Carlo De Lena, MD1, Letizia Imbriano1, Fabrizia D’Antonio1, MD, Laura Pieroni1
1Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance
Jacobo Mintzer, MD, MBA1, Mike Spline2, Erinn Bech, MPH3
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA; 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais
Catherine Adnet-Bonte, MD1, Brigitte Leprince1, Laetitia Breuilh, PhD1, Florence Pasquier, MD, PhD2,3
1Meotis, Centre Hospitalier Universitaire de Lille, France; 2Neurology Department, Centre Hospitalier Universitaire de Lille, France; 3Excellence Laboratory DISTALZ, Inserm U17, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer’s presentation
Jaime Perales, PhD1, MPH; W Todd Moore, MS1, Mariana Ramirez, LMSW1; Linda Lara, BA2; Erica Davis, BA2; Jason Resendez, MS2; Eric D Vidoni, PhD3
1University of Kansas Medical Center, Kansas-USA; 2Guadalupe Center, Kansas City-USA, 3Don Bosco Senior Center, Kansas City-USA, 4LatinosAgainstAlzheimer’s Coalition, Chevy Chase-USA

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer’s disease (AD)
John Alam1, Kelly Blachburn1, Nels Prins2,3, Philip Scheltens3
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P91 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Stephen Macfarlane, MBBS FRANZCP 1, Michael Kornhauser BPharm 1, Ella Modini BSc 1, Harald Hampel, MD PhD2, Stephan Toutain MS3, Tina LV4
1Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; 2Managing Partner, Recruitment Partners LLC, Columbia, MD, USA; 3Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study
Mariela Cajal-Berman, PhD1, Jessica Branning2, Vishnuharith Nitta, MS2
1Bioclinica Research, Orlando, FL, USA; 2ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials
Alberto Benussi, MD1, Antonella Alberici, MD1, Clarissa Ferrari, MD2, Valentina Cantoni, MD3, Valentina Dell’Era, MD1, Rosanna Turrone, MD4, Maria Sofia Cotelli, MD1, Giuliano Binetti, MD1, Barbara Paghera, MD1, Giacomo Koch, MD1, Barbara Borroni, MD1, Alessandro Padovani, MD, PhD5
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 2IFCNS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 3Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, 4Neurology Unit, Ospedale Vallecamonica, Esine, Brescia, Italy, 5Non Invasive Brain Stimulation Unit, IFCNS Santa Lucia Foundation, Rome, Italy, 6Stroke Unit, Policlinico Tor Vergata, Rome, Italy
P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials
Kenneth Stanley1, Carolina Rubel1, Lynne Hughes1
1IQVIA Project Leadership Unit

P95 - CSF biomarkers outcomes in the ETHERAL AD study
Harald Hampe1,2, Carlos Buesa3, Tamara Maes4, Mabel Arevalo5, Michele Lufino5, Roger Bullock5
1AXA Research Fund & Sorbonne University Chair, Paris, France, 2Sorbonne University, QRC, n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitie-Salpetriere Hospital, Paris, France, 3Brain & Spine Institute (ICM), INSERM U1127, CNRS UMR 7225 Paris, France, 4Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitie-Salpetriere Hospital, AP-HP, Paris, France, 5Oryzon Genomics SA, Barcelona, Spain

P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer’s Disease
Percy M Coloma1, Stephanie J. B. Vos1, Isabelle Bos2, Andy Simmons3, Rih Vandenberghe4, Philip Scheltens5, José Luis Molinuevo6,7, Flavio Nobili8, Sebastián Engelborghs9,10, Giovanni Frisoni11,12, Gaël Chetlet13, Alberto Lleó14, Anders Wallin15, Julius Popp16,17, Pablo Martínez-Lage18, Gonzalo Durán-Pacheco19, Pieter Jelle Visser20, Mark F Gordon21, Gerald Novak22
1Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, 2Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, 3Institute of Psychiatry, Kings College, London, UK, 4University Hospital Leuven, Leuven, Belgium, 5Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, 6Alzheimer’s disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain, 7Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, 8Clinical Neurology, Department of Neurosciences (DINOCM), University of Genoa and IRCCS Policlinico San Matteo Hospital, Genoa, Italy, 9Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium, 10Reference Center for Biological Markers of Dementia (BIODEM), Institute Bom-Bunge, University of Antwerp, Antwerp, Belgium, 11University of Geneva, Geneva, Switzerland, 12IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 13Inserm, INSERM UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France, 14Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 15University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, 16Geniatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, 17Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, 18CITA-Alzheimer Foundation, San Sebastian, Spain, 19Teva Pharmaceuticals, Malvern, PA, USA, 20Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders
Roger Bullock1, David Rotllant2, Michele Lufino2, Cristina Mascaro2, Carlos Buesa2, Tamara Maes2, Sonia Gutierrez2, Marta Valverde1, Tony Ramos3
1Oryzon Genomics, Barcelona, Spain, 2 Vall D’Hebron Hospital, Barcelona, Spain

P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer’s disease trials?
Piers Kotting, MBA1, Kris Beicher2, Adam Smith2, Clare Shaw, PhD2
1University of Exeter Medical School, Exeter, UK, 2University of Leeds, Leeds, UK, 3Institute of Psychiatry, University College London, London, UK

P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease
Smijlana Ristic1, MD, Mercè Boada2, MD, PhD2, Nathalie Pross, PhD2, Danielle Abi-Saab, PsyD2, Szofia Bullain, MD2, Mirjana Andjelkovic, PhD2, Paul Delmar2, PhD2, Carsten Hofmann4, PhD2, Alison Searle, BSc5, Monika Baudler, PhD2, Paulo Fontoura, MD, PhD1, Rachelle Doody, MD, PhD4
1F. Hoffmann-La Roche Ltd., Basel, Switzerland, 2Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain, 3Roche Products Ltd., Welwyn Garden City, UK, 4Genentech, Inc., South San Francisco, CA, USA

P100 - Study enrollment and Alzheimer’s disease pathology in relation to cohort type and participant characteristics in the EPAD Registry
Lisa Vermunt1, MD, Graciela Muniz-Terrera2, PhD2,3, Lea ter Meulen, MSc1, Colin Veal1, PhD1, José Luis Molinuevo, MD, PhD4, Pierre-Jean Ousset, MD5,6, Niels D Prins, MD, PhD2, David Porteous, PhD2, Craig W Ritchie, PhD2, Philip Scheltens, MD, PhD1, Gerald Luscan, MSc2, Anthony J Brookes, PhD2, Pieter Jelle Visser2, MD, PhD2
1VU University Medical Center, Amsterdam, Netherlands, 2University of Edinburgh, Edinburgh, Scotland, 3University of Victoria, Victoria, Canada, 4University of Cambridge, Cambridge, England, 5University of Leicester, Leicester, England, 6Barcelona Beta Brain Research Center, Barcelona, Spain, 7Clinic University Hospital, Barcelona, Spain, 8CHU Toulouse, Gerontopôle and INSERM UMR 1027, Toulouse, France, 9Brain Research Center, Amsterdam, Netherlands, 10Pfizer, Paris, France, 11Maastricht University, Maastricht, Netherlands

P101 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes
Richard E. Kennedy1, MD, PhD, Guoqiao Wang4, PhD, Mackenzie E. Fowler, MPh4, Gary R. Cutter, PhD, Lon S. Schneider, MD, MS4
1Department of Medicine, University of Alabama at Birmingham, USA, 2Division of Biostatistics, Washington University, St. Louis, USA, 3Department of Epidemiology, University of Alabama at Birmingham, USA, 4Department of Biostatistics, University of Alabama at Birmingham, USA, 5Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA
Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer’s disease clinical development
Olga Uspenskaya-Cadoz1, Yuliya Nigmatullina2, Kenneth Stanley3, Chaitanya Alamuri2, Penny Randall1, Sam Khinda1, Lanhui Wang1, Mengting Yang1, Carolina Rubel1, Lynne Hughes2, Tao Cao2, Michelle O’Keefe2, Nikhil Kayal2
1IQVIA CNS Center of Excellence, 2IQVIA Analytics Center of Excellence, 3IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation
Karen Holdridge MPH1, Roy Yaari, MD1, Brian A. Willis PhD1, Isabella Velona MS1, Paul Aisen MD2, Reisa Sperling, MD1
1Eli Lilly and Company, Indianapolis, USA, 2University of Southern California, San Diego, USA, 3Brigham and Women’s Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?
Karen Holdridge MPH1, Roy Yaari, MD1, Brian A. Willis, PhD1, Isabella Velona, MS1, Susan Mills1, Randall Bateman2
1Eli Lilly and Company, Indianapolis, USA, 2University of Southern California, San Diego, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?
Sean Stanton1, Dan Davis1, Vishnu Rukith Nitta, MS2, Jessica Branning, BS3, John Dwyer, JD3, Jason Bork, MBA1, James Taylor4, and George Vradenburg, JD5
1LifeCore Solutions, LLC, 2ClinCloud, LLC, 3Global Alzheimer’s Platform, 4Bioclinica Research, 5Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia
Kenneth Rockwood1, Justin Stanley1, Taylor Dunn1, Susan E Howlett1,2
1DGI Clinical Inc., Halifax, NS, Canada, 2Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer’s disease prevention: an effective recruitment strategy for preventive trials
Isabelle Carrie, PhD1, Julien Delrieu, MD2,3, Françoise Lala, MD1, Christophe Hein, MD1, Delphine Penneletier, PhD1, Pierre Jean Ousset, MD2,4, Bruno Vellas, MD, PhD2,3
1Gerontopole, Toulouse University Hospital, Toulouse, France, 2Inserm Unit 1027, Toulouse, France, 3University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer’s disease
Lars Lau Raket PhD1
1H Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer’s Disease
Delia A. Gheorghe, MSc1, Sarah Bauereimser, PhD1, John Gallacher, PhD1
1University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults
Alette Wessels, PhD1, Adrian Schembr, DPscyh1, Pav Kalinowski, PhD1, Reisa Sperling, MD1, Roy Yaari, MD1, Paul Aisen, MD4, David Barfield, MS1, Scott Andersen, MS1, John R. Sims, MD1, A4 Study Team, Paul Maruff, PhD2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate Ltd, New Haven, Connecticut, CT, USA, 3Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, 4Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials
Lucianne Dobson PhD1, Miguel Rosa Grilo MD1, Catherine Mummery PhD1
1Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer’s Disease Study
Adam Butler1, Denis Curtin, PhD1, Mackenzie Johnson1, and Jeff Lee1
1CRF, Brachet, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer’s disease
Steven E. Arnold, MD1, Rebecca A. Betensky, PhD1
1Massachusetts General Hospital and Harvard Medical School, Boston, USA, 2Harvard T.H. Chan School of Public Health, Boston, MA
Theme 2. Clinical trials: Results

P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer’s disease and depressive symptoms: interim results of an observational study
Eduardo Cumbo MD1, Silvia Cumbo MD1, Salvatore Torregrossa PsyD1, Daniela Migliore PsyD1
1Neurodegenerative Disorders Unit, ASP, Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer’s Disease (CPAD) consortium’s vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database
Volker D. Kern, PhD1, Stephen P. Arneric, PhD1, Maria C. Carrillo, PhD2, James Hendrix1, PhD2, Billy Dunn1, MD2, Stacie Weninger, PhD1, Jeffrey A. Kaye, MD1, Daniel R. Karlin, MD1, Lisa H. Gold, PhD1, Michael Gold, MD1, Samantha Budd Haeberlein, PhD1, Molly Shea, PhD1, George Vradenburg1, Daniela J. Conrado, PhD1, and Klaus Romero, MS, MD1
1Critical Path for Alzheimer’s Disease Consortium, Critical Path Institute, Tucson, AZ, USA, 2Alzheimer’s Association, Chicago, IL, USA, 3U.S. Food and Drug Administration, Silver Spring, MD, USA, 4Prime Biomedical Research Initiative, Cambridge, MA, USA, 5Oregon Health & Science University, Portland, OR, USA, 6Pfizer, Boston, MA, USA, 7Merck & Co., Inc., Kenilworth, NJ, USA, 8AbbVie, North Chicago, IL, USA, 9Biogen, Cambridge, MA, USA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 11UsAgainstAlzheimer’s, Washington, DC, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer’s disease: A post-hoc analysis of a multicenter, randomized trial
Yun Jeong Hong, MD, PhD1,2 Hyun Jeong Han, MD, PhD3, Young Chul Youn, MD, PhD3, Kyung Won Park, MD, PhD3, Dong Won Yang, MD, PhD3, Sang Yun Kim, MD, PhD1, Hwa Jung Kim, MD, PhD1, Ji Eun Kim, MD, PhD1, Jae-Hong Lee, MD, PhD1, the ODESA study group
1Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2Biomedical research institute, Pusan National University Hospital, Pusan, 3Neurology, Danyang University College of Medicine, Gyeonggi Province, South Korea

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers
Stephen Lowe1, Jeffrey Dage2, Ann Cleverley3, Albert Lo4, Elizabeth S. LaBell4, Hakop Gevorkyan4, Stanford Jhee5, Larry Huffman6, Boris Calderon7, Brian A. Willis2
1Lilly Centre for Clinical Pharmacology, Singapore, 2Eli Lilly and Co, Indianapolis, IN, 3Eli Lilly and Co, Erl Wood, UK, 4California Clinical Trials Medical Group, Inc., 5PAREXEL Early Phase, Glendale, CA, USA

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses
Stefan Viktor Vormfelde, MD/PhD1, Nicole Pezous1, Gilbert Lefèvre1, Carine Kolly1, Ulf Neumann, MD2, Pierre Jordaan, MD2, Guenter Heimann, MD2, Mike Ufer, MD/PhD1, Ana Graf2, MD1, Eric Legangneux, MD1
1Novartis Institutes for BioMedical Research, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors
Kenneth Rockwood, MD2, Justin Stanley, BSc1, Susan E Howlett, PhD1,3
1DCI Clinical Inc, Halifax, NS, Canada, 2Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, 3Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase I Clinical Studies in Alzheimer’s Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640
Marc Cantillon, MD1, Hiroyuki Shimada, MD, PhD2, Kenichiro Sugiyama, Phar.B.3, Wei Sun, PhD.D.1, Yoshiumi Ouchi, M Eng1, Katsuyoshi Tsuhii, MSc1, Gemma Clark, RGN RM4
1Kyowa Kirin Pharmaceutical Development, Inc., USA, 2Osaka city university hospital, Osaka, Japan, 3Kyowa Hakko Kirin Co., Ltd, Japan, 4Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase Ib study
Philipp von Rosenstiel MD1, Tianle Chen, PhD1, John O’Gorman, PhD1, Min Yee, PharmD1, Carmen Castrillo-Viguera, MD, PhD1, Claudia Prada, MD1, Christoph Hoch, MD1, Roger M Nitsch, MD1, Samantha Budd Haeberlein, PhD1, Alfred Sandrock, MD, PhD1
1Biogen, Cambridge, MA, USA, 2Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
P109 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?
Kathleen M. Hayden, PhD1, José A. Luchsinger, MD2; Stephen R. Rapp, PhD1; Delilah R. Cook, CCRP1; Rebecca H. Neiberg, MS1; Judy L. Bahnsen, BA1; Tara D. Beckner1; Jerry M. Barnes, MA1; and Mark A. Espeland, PhD1 for the Look AHEAD MIND Study Group

Wake Forest School of Medicine, Winston-Salem, USA, 2Columbia University, New York, USA

P110 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers
Tim Tasker MBBS1, Jan Liptrot PhD, Charlotte Balthier PhD2, Ellen 't Hart PhD2, Erica Klaassen PhD2, Samantha Prins MD2, Thalia van der Doef PhD2, Mike Walker1, Giles A. Brown PhD1, Alastair Brown PhD1, Miles Congreve PhD1, Malcolm Weir PhD2, Fiona H. Marshall PhD1, David M. Cross PhD1, Geert Jan Groeneveld MD, PhD2, Pradeep. J. Nathan PhD1, a

Sosei Heptares, Cambridge UK, 2Centre for Human Drug Research (CDHR), Leiden, Netherlands, 3Department of Psychiatry, University of Cambridge, UK, 4Cross Pharma Consulting Limited, Cambridge, UK

P111 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings
Jessica B. Langbaum, PhD1, Jason Karlawish, MD2, Scott Roberts, PhD1, Angela Bradbury, MD2, Scott Kim, MD, PhD1; Elisabeth McCarty Wood, MS1, Carolyn Langlois, MA1; Fonda Liu PharmD1, Marie-Emmanuelle PhD1, Marie-Laure Rouzade-Dominguez, PhD1; Angelita Caputo, PhD1; Mauritz Bezuidenhoudt, M.Sc1, Cristina Lopez-Lopez, MD, PhD1, Anna Graf, MD1, Pierre N. Tariot, MD1, Eric M. Reiman, MD1

1Banner Alzheimer’s Institute, Phoenix, USA, 2University of Pennsylvania, Philadelphia, USA, 3University of Michigan, Ann Arbor, USA, 4National Institutes of Health, Bethesda, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, USA, 6Novartis Pharma AG, Basel, Switzerland

P112 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer’s disease with low dose hydromethylthionine
Bjoern Schelter, PhD1,2, Claude Wischik, MD, PhD1,2

1Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, 2TauRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI
Carine Federspiel, PhD1, Elisabeth Bourretel, PhD1, Jean-Paul Steinmetz, PhD1

1Centre for memory and mobility, ZithaAktiv, Luxembourg, 2ZithaSenior, Research&Development, Luxembourg

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer’s Disease: Consistency of Multiple Evaluation Analyses
Daniel Alkon, PhD1, LJ Wei, PhD2, Richard Thompson, PhD3

1Neurotope,Inc, 2Harvard University, 3Johns Hopkins University

LBP15 - Enterovirus might be involved in Alzheimer’s disease - results from a phase IIa trial evaluating Apovir, an antiviral drug combination
Lars-Olof Wahlund, MD, PhD1, Lars Lindqvist MD, PhD2, Mikael Åström MSc, PhL1, Jacob Westman PhD1, Roger Bullock MD, PhD2, Suzanne Hendrix1, Nina Lindblom, Ph.D1

1Karolinska University Hospital, Huddinge, Sweden, 2Karolinska University Hospital, Huddinge, Sweden, 3StatCons, Limhamn, Sweden, 4Apodemus AB, Söna, Sweden, 5Roger Bullock Consulting Ltd, Swindon, UK, 6Pentara Corporation, Salt Lake City, USA

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer’s disease
Samer Katra, MD1, Casey Lynch1, Mark Ryder, DMD2, Ira Goodman, MD1, Steve Thien, MD4, Steve Dominy, MD1

1Cortexyme, S. San Francisco, CA, 2UCSF, San Francisco, CA, 3Bioclinica, Orlando, FL, 4Pacific Research Network, San Diego, CA

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up
Miquel Aguilar MD, PhD1 and Paquita Soler. Nurse1

1Àptima Mutua Terrassa, Catalunya, SPAIN
LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial  
Carmen Valcarce, PhD1, Imogene Dunn, PhD1, Tom Soeder, MS2, and Aaron Burstein, PharmD2  
1VivTherapeutics LLC, High Point, NC, USA, 2CATO Research Ltd, Durham, NC, USA

LBP19 - Aducanumab 48-month analyses from PRIME, a Phase Ib study in patients with early Alzheimer’s disease  
Philipp von Rosenstiel, MD1, Samantha Budd Haeberlein, PhD1, Carmen Castrillo-Vigueria, MD1, Tianle Chen, PhD2, John O’Gorman, PhD2, Raj Rajagovindan, PhD1, Dalshaben Patel, PhD2, Guanfang Wang, PhD2, Spyros Chalkias, MD1, LeAnne Sjordos PharmD2, Claudia Prada, MD1, Christoph Hoch, MD1, Roger M Nitsch, MD2, Alfred Sandrock, MD, PhD2  
1Biogen, Cambridge, MA, USA, 2Biogen, Maidenhead, UK, 3Cytel, Cambridge, MA, USA, 4Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LBP20 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease  
Bjørn Sperling, MD1, Lars Østergaard Pedersen, PhD1, Neli Boneva, MD1, Dorthe Daugaard, MD1, Yudong Zhao, PhD1  
1H. Lundbeck A/S, Valby, Denmark

LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer’s Disease Colombia Trial  
1Banner Alzheimer’s Institute, Phoenix, AZ, USA, 2Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO, 3Genentech Inc., South San Francisco, CA, USA, 4Roche Products Ltd, Welwyn Garden City, UK, 5University of California, San Diego, CA, USA, 6Hospital Pablo Tobon Uribe, Medellin, CO, 7Harvard Medical School and Massachusetts General Hospital, Boston MA, USA
Theme 3. Clinical trials: Imaging

P10 - Diagnostic accuracy of [18F]FCI19S PET for identifying Alzheimer’s disease
Byung Hyeon Byun, MD, PhD1, Sang Moo Lim, MD, PhD1
1Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea
Yu Yong Choi1, Byoung C. Kim2, Seong-Min Cho3, Kee Hyung Pahn4, Kyu Yeong Choi, Kun Ho Lee4
4National Research Center for Dementia, Chosun University, Gwangju, South Korea, 1Department of Neuroradiology, Chosun National University Hospital, Gwangju, South Korea

P62 - Impact of cerebral blood flow changes on 18F-Frobetaben SUVR. A simulation study
Santiago Bullich, PhD1, Norman Koglin, PhD1, Susan De Santi, PhD1, Georg A. Becker, PhD2, Audrey Perrotin, PhD2, Aleksandar Jovaleh, PhD3, Andrew Stephens, MD, PhD1, Henryh Barthel, MD, PhD1, Osama Sabri, MD, PhD1
1Piramal imaging GmbH, Berlin, Germany, 2Piramal Pharma Inc., Boston, MA, USA, 3Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia
Ruben Smith, MD, PhD1, Alexander F Santillo, MD2, Maria Landqvit Waldö2, MD, PhD2, Oskar Hanssö2, MD, PhD1
1Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, 2Memory Clinic, Angelholm Hospital, Angelholm, Sweden, 3Memory Clinic, Skåne University Hospital, Malmö, Sweden

P113 - Predicting amyloid burden from cognitive assessment
Donald R. Royall, MD, PhD1, Raymond F. Palmer, PhD1 for the Alzheimer’s Disease Neuroimaging Initiative
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family and Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer’s disease
Federica Ribald, MS1,2, Moira Marizzoni, PhD1, Valentina Garibotto, MD3, Michela Pievani, PhD1, Giovanni B Frisoni, MD3
1IRCCS Fatebenefratelli, Brescia, Italy, 2University of Brescia, Brescia, Italy, 3Geneva University Hospitals, Geneva, Switzerland

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data
David Scott, PhD1, Kataryna Adamczuk, PhD2, Beth Gorman, BS CNMT2, Maureen Runkle, BS CNMT2, Joyce Suhy, PhD3 and the Alzheimer’s Disease Neuroimaging Initiative
1Bioclinica, Newark, CA, USA, 2Bioclinica, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?
Sergey Shcherbinin, PhD1, Michael J. Pontecorvo, PhD2, Ming Lu, MD, MS, MPP1, Michael D. Devous Sr, PhD2, A. Joshi, PhD2, Sudeepi Southekal, PhD2, Emily C. Collins, PhD1,2, Adam S. Fleisher, MD2, Mark A. Mintun, MD1,2
1Eli Lilly & Co, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans
Gemma Salvadó MSc1, Chris Foley PhD1, Elisabetta Grecchi, PhD1,2,3, M. Jorge Cardoso, PhD1,2,3,4, Isadora Lopes-Alves, PhD2, Pawel Markiewicz, PhD1,2, Carles Falcon, PhD1, Mark Battle MSc1, Adriaan A. Lammertsma, PhD1,2, Mark Schmidt, MD, PhD2,3, José Luis Molinuemo VD Ph1,2,3, Frederik Barkhof, MD, Ph1,2,4, Juan Domingo Gispert, PhD1
1BarcelonaBeta Brain Research Center, Barcelona, Spain, 2GE Healthcare, Amersham, United Kingdom, 3XiCO, London, United Kingdom, 4King’s College London, London, United Kingdom, 5University College London, London, United Kingdom, 6VU Medical Center, Amsterdam, The Netherlands, 7Janssen Pharmaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer’s disease
Andrew Stephens1, Andre Mueller, Santiago Bullich1, Mathias Berndt1, John Selby2, Olivier Barret2, Jennifer Madonia2, Heiko Kroth1, Andrea Pfeifer3, Andreas Muhs1, Gilles Tamagnan4, Kenneth Marek5, Ludger Dintelborg1
1Piramal Imaging, Berlin, Germany, 2Iniviva, New Haven, USA, 3AC Immune SA, Lausanne, Switzerland

P119 - Cut-off for 18F-flutemetamol SUVR with white matter reference region
Kataryna Adamczuk, PhD1, David Scott, PhD1, Ben Newton, PhD3, Joyce Suhy, PhD2, Michael Egan, MD2, Cyrille Sur, PhD2
1Bioclinica, Newark, CA, USA, 2Merc Sharp & Dhone, Kenilworth, NJ, USA, 3General Electric Health Care, Amersham, UK

P120 - Amyloid PET Imaging in a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with UB-311
Hui Jing Yu1, Hui-Chen Chen1, Jacob Hesterman2, Jack Heimann2, Sean Holmes2, Alex Whittington2, Xue Wang2, Roger Gunn2, Ajay Verma2
1United Neuroscience Inc, Hauppauge, NY, USA, 2Iniviva, A Konica Minolta Company, Boston, MA, USA
**CTAD 2018 POSTERS PRESENTATION**

**PI21 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study**
Andrea Pilotto1,2 and Francesca Schiano di Cola1, MD and, MD; Enrico Premi1, MD; Roberto Grassol PsyD, Rosanna Turron1e, PsyD; MD; Stefano Gippini1, MD, Andrea Scalvini1, MD; Elisabetta Cottini1, Carolina Paghera1, Laura Bonanni1, PhD; MD; Maria Cristina Rizzetti1, PhD; Barbara Borroni1, MD; Alessandro Padovani1, PhD, MD
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 2Parkinson’s Disease Rehabilitation Centre, FERB ONLUS S.Isidoro Hospital, Trescore Balneario (BG), Italy; 3Nuclear Medicine Unit, University of Brescia, Brescia, Italy; 4Department of Neuroscience Imaging and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti, Italy

**PI22 - Very early detection and treatment monitoring of Alzheimer’s Disease in the retina by multimode, hyperspectral confocal scanning ophthalmoscopy**
Daniel L. Farkas1,2, Fartash Vasefi, PhD1, Jeanne M. Fontana, MD, PhD1
1The Brain Window, Inc., Sherman Oaks CA, USA; 2University of Southern California, Los Angeles CA, USA

**PI23 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume**
Mirza Faisal Beg, PhD1, Da Ma, PhD, Karteek Popori1, Mahadev, MD2, Lei Wang, PhD3
1School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada; 2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; 3Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

**PI24 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer’s Disease Neuroimaging Initiative**
Eddie Stage1, Diana Svaid PhD1, Sophie Sokolow PhD MPharm1,6, Shannon L. Rioscher PhD1, Kristzina Marosi2, Kwangsik Nho PhD1, Jerome I. Rotter MD1,4, Andrew J. Saykin PsyD1, Liana G. Apostolova MD MS1
1Indiana Alzheimer Disease Center, Indianapolis, IN, USA; 2UCLA School of Nursing, Los Angeles, CA, USA; 3Division of Genomic Outcomes, Department of Pediatrics and medicine, Harbor-UCLA Medical Center, Torrance, CA, USA; 4Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA; 5UCLA Brain Research Institute, Los Angeles, CA, USA; 6UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

**Late Breaking Posters**

**LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer’s Disease**
Sheng-Min Wang, MD, PhD1, Yoo Hyun Um, MD, PhD2, Chang-Ul Lee MD, PhD3, and Hyun Kook Lim, MD, PhD4
1Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; 2St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea; 3Department of Psychiatry, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

**LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer’s dementia in an Asian Clinic Cohort**
Nagaedran Randiah
National Neuroscience Institute, Singapore

**LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets**
Susan Abushakra MD1, Luc Bracoud MS2, Joel Schaerer2, Aidan Power MD1, John Hey PhD1, David Scott PhD1, Joyce Suhy PhD3, Martin Tolar MD PhD1 & the Alzheimer Disease Neuroimaging Initiative (ADNI)
1Alzheon Inc., Framingham, MA, USA; 2Bioclinica, Lyon France; 3Bioclinica, Newark CA, USA

**LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study**
Gregory Klein1, Ruben Smith2, Sebastian Palmqvist3, Niklas Mattsson1, Daniela van Westen2, Olof Strandberg2, Jonas Jögi3, Tomas Ohlsson3, Edilio Borroni1, Preciosa Coloma1, Erlik Stomrud1, Oskar Hansson3
1Roche Pharma Research and Early Development, Basel, Switzerland; 2Clinical Memory Research Unit, Lund University, Sweden
Theme 4. Clinical trials: Biomarkers including plasma

**P1 - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment**

Shani Waninger, Ph.D.¹, Chris Berkta, Amir Meghdadi, Ph.D.¹, David Salat, M.D.² and Ajay Verma, M.D., Ph.D.³

¹Advanced Brain Monitoring, Inc., Costa Mesa, CA, ²MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, ³United Neuroscience, Dublin, Ireland

**P4 - High correlation in the Aβ40 and Aβ42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS**

José A. Allué, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.

Araclon Biotech S.L., Via Hispanidad 21, 50.009, Zaragoza, Spain

**P22 - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI**

Kazuki Suzuki, MD, PhD,¹ Ryotaro Ihara, MD, PhD,² Atsushi Iwata, MD, PhD,³ Tatsushi Iwatsubo, MD, PhD,⁴ Kenji Ishii, MD,⁴ Tatsushi Itakauchi, MD, PhD,⁴ Ryozo Kuwano, MD, PhD,⁴

¹Department of Alzheimer’s Disease Neuroimaging Initiative, ²The University of Tokyo, Tokyo, Japan, ³Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ⁴Niigata University, Niigata, Japan

**P28 - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β-Amyloid 1-40 assays**

Manu Vandijck, Martine Dauwe, Rosina Gregirecht, Els Huyck, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjsek

Fujirebio Europe NV, Ghent, Belgium

**P30 - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888**

Norman Relkin, MD, PhD,¹ Dan Li, PhD,¹ Joshua Costin, PhD,² David Wyatt, MD³

¹Relkin Consulting LLC, Harrington Park, NJ 07640, ²Herbs &Sciences Group, Naples FL, USA, ³Syneos Health, Miami FL, USA

**P39 - Diagnostic biomarkers’ clinical applicability in early onset Alzheimer’s disease**

Neus Falgás, Raquel Sánchez-Valle, Mircea Balasa, Sergi Borrego, Magdalena Castellví, Adrià Tort-Merino, Jaume Olives, Beatriz Bosch, Guadalupe Fernández, Francisco Lomeña, Núria Bargallo, Albert Lladó

¹Alzheimer’s disease and other cognitive disorders Unit, IDIBAPS, Hospital Clinic Barcelona. ²Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute. Trinity College Dublin, Ireland. ³Nuclear Medicine Department. IDIBAPS. Hospital Clinic de Barcelona. ⁴Image Diagnostic Centre. IDIBAPS. Hospital Clinic de Barcelona

**P44 - Inverse association between Aβ42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study**

Iziar de Rojas, MSc, Judith Romero, MSc, Octavio Rodriguez-Gomez, MD, Pedro Pesini, PhD, Angela Sanabria, PhD, Alba Pérez-Cordon, MSC, Carla Adelnour, MD, PhD, Isabel Hernández, MD, PhD, Maitee Rosende-Roca, MD, Ana Espinosa, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Oscar Sotolongo-Grau, PhD, Susana Ruiz, MSc, Laura Montreuil, MLT, Elvira Martin, MSc, Esther Peleja, Francisco Lomeña, MD, PhD, Francisco Campos, PhD, Assumpta Vivas, MD, Marta Gómez-Chiari, MD, Miguel Angel Tejero, MSc, Joan Giménez, MD, Virginia Pérez-Grijalba, PhD, Marta Marquié, MD, PhD, Gemma Monté-Rubio, PhD, Sergi Valero, PhD, Adelina Orellana, PhD, Lluis Tàrraga, MSc, Manuel Sarasa, PhD, Agustín Ruiz, MD, PhD, Mercè Boada, MD, PhD, on behalf of the FACEHBI study

¹Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain. ²Araclon Biotech S.L. Vía Hispanidad 21, 50.009, Zaragoza, Spain. ³Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain. ⁴Department of Diagnostic per la Imatge. Clínica Corachan, Barcelona, Spain

**P57 - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study**

Oskar Hansson, MD PhD,¹ Katharina Zinth, MSc,² Simone Wahl, PhD,² Monika Widmann, ChTech,² Sandra Rutz, PhD,² Maryline Simon, PhD,³ Kaj Blennow, MD PhD,²,³ Erik Stromrud, MD PhD,²,³

¹Clinical Memory Research Unit, Lund University, Malmö, Sweden. ²Memory Clinic, Skåne University Hospital, Malmö, Sweden. ³Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁴Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁵Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁶Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany.

**P64 - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer’s Disease biomarkers in clinical practice**

Oskar Hansson, MD PhD,¹ Erik Stromrud, MD PhD,² Sandra Rutz, PhD,² Valeria Lifihe, PhD,² Ekaterna Bauer MBA PhD,² Udo Eichenlaub, PhD,² Richard Battria, MD PhD,² Ekaterna Manuilova, MSc,² Mehmet Can, Mert PhD,² Simone Wahl, PhD,² Kaj Blennow, MD, PhD,³

¹Clinical Memory Research Unit, Lund University, Malmö, Sweden. ²Memory Clinic, Skåne University Hospital, Malmö, Sweden. ³Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁴Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁵Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. ⁶Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany.
P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatolgy and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province 710000, China; 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China; * Corresponding author

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic target
Lynn Bektri1, Rumana Akhter1, Yvonne Shao1, Maria Khrestian1, Giana D’Aleo1, Shane Formica1, James B. Leverenz2
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; 2Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer’s centre
Nataliya Mikhaylova1
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio

P78 - Modifiable Alzheimer’s risk biomarkers
Christine Canez, Alon Seifan, MD, Krista Ryon1, Elizabeth Maiche MCMSc, PA-C4
1Hunter College, NY; 2NeuralWells Free, Ft. Lauderdale, Florida; 3Hunter College, NY; 4NeuralWells Free, Ft. Lauderdale, Florida

P81 - Serum NFL, TAU, GFAP and UCHL-1 in Alzheimer disease patients with different decline profile
Mélissa Jacob, MD;2,3, Alejandra Macesi, PhD,4, Siene Richaert PhD1, Audrey Gabelle MD, MD, PhD1,2,4, Sylvain Lehmann MD, PhD2,3
1Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France; 2Université de Montpellier, MUSE, Montpellier, France; 3Inserm U1183 IRMB, Montpellier, France; 4Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluid
Eugene Vanmechelein, PhD1, Jeroen Vanbrabant, PhD1, Naomi De Roeck, BcS2, Maria Bjertne, PhD2, Sebstianang Engborgers, MD, PhD2,3, Ann De Vos, PhD1
1ADx NeuroSciences NV, Ghent, Belgium; 2Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; 3Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down Syndrome. A cross-sectional study
Maria Carmona-Iragui, MD, PhD2,3, Bessy Benejam, MSc2, Susana Fernández, MD2, Laura Videla, MSc2,3, Isabel Barroeta, MD, PhD1, Daniel Alcolea, MD, PhD1, Jordi Pegueroles, MSc1, Laia Muñoz, MSc1, Olivia Belbin, PhD1, Jordi Claramón, PhD1, Man John de Leon, Ed.D2, Sebastián Videla, MD, PhD1,2, Alejandra Maleska Macesi, MSc1,2, Christoph Hirtz, PhD1, Constance Delaby, PhD1, Sylvain Lehmann, PhD1, Rafael Blesa, MD PhD1,2, Alberto Lleó, MD, PhD1,2, Juan Foroza, MD PhD1,2,3
1Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Spain; 2Barcelona Down Medical Center: Fundació Catalana de Síndrome de Down, Barcelona, Spain; 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; 4New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry, New York, USA; 5Clinical Research Support Unit, Bellvitge University Hospital / Bellvitge Biomedical Research Institute (IDIBELL) / University of Barcelona, Barcelona, Spain; 6Universtité de Montpellier, CHU de Montpellier, France

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer’s Disease in carriers and non-carriers of the ApoE4 risk allele
Richard Pitner PhD1, Ganna Leonenko1, Rebecca Simms1, Paula Daunt PhD1, Greg Davidson PhD1, Alex Gibson PhD1, Olusgun Oshota PhD1, Maryam Shoai PhD1, Kevin Banits1, Simon M Laws PhD1, Zsuzsanna Nagy1 and John Hardy, PhD, DSc2, Julie Williams PhD1,2, Valentina Escott-Price, PhD1
1Cardiff University, United Kingdom; 2Cytox Ltd, UK; 3Oxford, United Kingdom; 4UCL Institute of Neurology, London, United Kingdom; 5Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; 6University of Birmingham, United Kingdom; 7Dementia Research Institute, Cardiff, United Kingdom

P128 - Do short Aβ-peptides impact the time course of cognitive decline? An ADNI analysis
Markus von Ickien, PhD1, Paul Delmar, PhD1, Katharina Buck, PhD1, Charlotte Schärfe2, Simone Wahl, PhD2, Karlheinz Baumann, PhD2, Irene Gerlach, PhD1, Tania Nikolcheva, MD, PhD1
1pRED NORD, Roche Innovation Center Basel - Switzerland; 2Biotravas and Data Management, Roche Innovation Center Munich - Germany

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer’s disease
SangYun Kim, MD, PhD1,2, Sungmin Kang, MS1, Seong Soo A. An, PhD1, Young Chul Youn, MD, PhD1
1Department of Neurology, Seoul National University College of Medicine; 2Clinical Neuroscience Center, Seoul National University Bundang Hospital; 3PeopleBio Company, 4Department of Bionano Technology, Gachon Medical Research Institute, Gachon University; 5Department of Neurology, Chung-Ang University College of Medicine
P130 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer’s disease patients
Giacomio Koch, MD, PhD1,2, Caterina Motta MD1, Francesco Di Lorenzo MD1, Maria Concetta Pelliciari PhD1,2, Sonia Bonni PhD1,2, Silvia Picazio PhD1,2, Carlo Cataglielide1,2, Alessandro Martorana MD1

1Department of Behavioral and Clinical Neurology, 2Santa Lucia Foundation IRCCS, Rome, Italy, 3University of Tor Vergata, Rome, Italy

P131 - Non-core biomarkers (neurofilament light, neurogranin, I4-3-3 and YKL-40) in the Alzheimer’s disease continuum, frontotemporal dementia and prion diseases diagnosis
Anna Antonell1, PhD1, Adrià Tort, MSc1, José Rios, MSc2, Sergi Borrego, MD1, Mircea Balasa, MD, Cristina Muñoz-García1, Beatriz Bosch, PhD, Neus Falgàs, MD1, Lorena Rami, PhD1, Kaj Blennow, MD, PhD1, Henriët Zetterberg, PhD4,5, José Luis Molinuevo, MD, PhD1, Albert Lladó, MD, PhD1, Raquel Sánchez-Valle, MD, PhD1

1Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic. IDIBAPS, Barcelona, Spain, 2Medical Statistics Core Facility, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic. Barcelona. Biosatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, 5Department of Molecular Neuroscience, University College London, London, UK

P132 - Amyloid blood biomarker detect Alzheimer’s disease
Klaus Csernert, Prof. Dr.

1Ruhr-Universität Bochum, Bochum, Germany

P133 - Early diagnosis of Mild Cognitive Impairment and Alzheimer’s disease based on salivary lactoferrin
Eva Carro1, Gorha Orive2

1Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imos12), Madrid, Spain, 2Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain, 3Networked Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain

Anna Antonell1, PhD1, Raquel Sánchez-Valle1, MD, PhD1, Neus Falgàs, MD1, Lorena Rami, PhD1, Debayan Datta, PhD2, Lluís Armengol, PhD2, Sergi Borrego, MD1, Guadalupe Fernández, Beatriz Bosch, PhD1, Jaume Olivés, Cristina Muñoz-García1, María León1, Magdalena Castellví1, Adrià Tort1, Albert Lladó, MD, PhD1

1Alzheimer’s disease and other cognitive disorders Unit. Hospital Clinic. IDIBAPS. Barcelona, Spain, 2qGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat, Spain

P135 - The future of blood-based histrone biomarkers in Alzheimer’s disease
Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet

Center of Cognitive Neurology, Lariboisière Hospital, AP-HP, University of Paris Diderot, Paris France

P136 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects
Charlotte E. Teunissen, PhD, Elisabeth Thijssen, MSc2, Inge M. W. Verberkt, MSc2, Hugo Marcel Vanderstichele, PhD2, Hans Heijst2, Harry Twaalfhoven1, Kimberley Mauroo BSc1, Philip Scheltens, MD, PhD1, and Erith Stoops, Eng2

1Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, 2Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, 3ADx NeuroSciences, Gent, Belgium, 4Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

P137 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu1, Yue-Ping Liu1

1State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province China, 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China. * Corresponding author

P138 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer’s Disease
Jagan A Pillai MBBS PhD2,3, James Bena MS1, Lynn M Bekris PhD1,2, James B Leverenz MD1,2

1Lou Ruvo Center for Brain Health, 2Neurological Institute and 3Department of Neurology, 4Quantitative Health Sciences, 5Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

P139 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation
Tharich A, Pascoaid MD1, Sulantha Mathataaraarchchi MSc1, Mira Chamoun PhD2, Joseph Therriault BSc1, Robert Hopewell PhD1, Cassan Massarweh PhD1, Andrea L Benedet1, MSc, BSc, Min Su Kang1, Serge Gauthier1, MD, Pedro Rosa-Neto1, MD, PhD

1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada
Late Breaking Posters

**LBP25 - Discovery of AN Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain**

John A. Hey, Petr Kocis, Jakub Hort, Susan Abushalalr, Aidan Power, Martin Vyhnahe, Jeremy Y. Yu and Martin Tolar

1Alzheimer, Inc, Framingham, MA, USA, 2International Clinical Research Centre, St. Anne’s University Hospital Brno, Brno, Czech Republic, 3Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic

**LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum**

Gregory Penner, Soizic Lecocq, Anaëlle Chopin, Simone Lista, Andrea Vergallo, Enrica Cavedo, Francois-Xavier Lejeune, and Harald Hampel

The INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

1NeoNeuro SAS, Villejuif ; Bio Part, Villejuif, France, 2AXA Research Fund & Sorbonne University Chair, Paris, France, 3Sorbonne University, CRC n° 2L, Alzheimer Precision Medicine (APM), AP-HP, Pitie-Salpetriere Paris, France, 4Brain & Spine Institute (ICM), INSERM U127, CNRS UMR 7225, Paris, France, 5Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitie-Salpetriere Hospital, AP-HP, Paris, France

**LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer’s disease for potential use in clinical trials**

Alberto Lleo, MD, PhD, Raúl Núñez-Llaves, Daniel Alcolea, MD, PhD, Marti Colom-Cadena, PhD, Laia Muñoz, Marta Querol-Vilaseca, Jordi Pegueroles, Lorena Rami, PhD, Albert Liadó, MD, PhD, José L. Molinuevo, MD, PhD, Mikael Tainta, MD, PhD, Jordi Clarimón, PhD, Tara Spire, MD, Blesa MD, PhD, Juan Fortea, MD, PhD, Pablo Martínez-Lage, MD, PhD, Raquel Sánchez-Valle, MD, PhD, Alex Bayes, PhD, Olivia Belbin, PhD.

1Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, 3Biomedical Research Institute Sant Pau (IDIBAPS), Barcelona, Spain, 4Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital-Clinic Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 5Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, 6Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IDIBAPS), Barcelona, Spain

**LBP28 - Diminished platelet-derived hsa-mir-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer’s disease**

Katrin Beyer, PhD, Ana Gámez-Valero, PhD, Jaume Campdelacreu, MD, PhD, Dolores Vilas, MD, PhD, Lourdes Ispierto, MD, PhD, Jordi Gascón-Bayarri, MD, Ramón René, MD, PhD, Ramiro Álvarez, MD, Maria P Armengol, PhD, Francesc E. Borràs, PhD

1Department of Pathology, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, 2REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain, 3Department of Neurology, Hospital Universitari de Bellvitge, I Hospitaller de Lleida, Spain, 4Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Genomic and Microscopy facilities, Institut Investigació Ciències de la Salut Germans Trias i Pujol (ICTP), Badalona (Barcelona), Spain

**LBP29 - Development of polygenic risk scores (PRS) for common neuropathology**

Julie Collens, PhD, Milte Nalis, PhD, Marcel van der Brug, PhD

1Vivid Genomics, Inc. San Diego, CA, USA

**LBP30 - The Italian Inter-Societal consensus framework for the biomarker-based diagnosis of mild cognitive impairment**

Marina Boccardi, PhD, Chiara Baldo, PhD, Cristina Nicolosi, MS, Cristiana Festari, MS, Angelo Bianchetti, MD, Stefano Cappa, MD, Davide Chiassarini, PhD, Andrea Falini, MD, Ugolino Guerra, MD, Flavio Nobili, MD, Alessandro Padovani, MD, Giulia Maria Sancesario, PhD, Francesca Benedetta Pizzini, PhD, Alberto Bellamore, MD, Marcello Ciaccio, MD, Orazio Schillaci, MD, Marco Trabucchi, MD, Fabrizio Tagliavini, MD, Giovanni Battista Frisoni, MD

1Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 2LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, 3University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy, 4Medicine and Rehabilitation Department, Istituto Clinico San Anna, Brescia, Italy, 5Italian Psychogenetic Association (AIP), Brescia, Italy, 6ECS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy, 7Italian Society of Neurology, Association for the Study of the Dementias (SINdem), Italy, 8Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy, 9Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Laboratory Medicine (SIBioC), Italy, 10Division of Neuroscience, IRCCS San Raffaele, Milan, Italy, 11Vita-Salute San Raffaele University, Milan, Italy, 12Neurorehabilitation Unit, IRCCS San Raffaele hospital, Milan, Italy, 13Italian Association of Neurorehabilitation (AINR), Italy, 14Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy, 15Italian Association of Nuclear Medicine (AImN), Italy, 16Clinical Neurology, Dept of Neuroscience (DINOQM), University of Genova, Italy, 17IRCCS Ospedale Policlinico San Martino, Genova, Italy, 18Neurology Clinic, Department of Clinical and Experimental Sciences, Brescia, Italy, 19Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy, 20Department of Neuroimaging, General Hospital, Verona, Italy, 21Department of Diagnostics for Immagini, IRCCS Ospedale Classificato «Sacro Cuore - Don Calabria», Negro, Verona, Italy, 22Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy, 23Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy, 24Tor Vergata, Rome University, Rome, Italy, 25Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy, 26Memory Clinic, University Hospital, Geneva, Switzerland

**LBP31 - Secondary structure of Aβ as blood biomarker**

Klaus Gerwert

Department of Biophysics Ruhr University Bochum, Germany
CTAD 2018

POSTERS PRESENTATION

LBP32 - BDNF as a biomarker for the effects of p38 MAPKα inhibition on IL-1β-induced impairment of hippocampal synaptic plasticity
John Alam MD1, Charlotte Teunissen PhD2, Niels Prins MD PhD34, Hui-May Chu PhD2, Philip Scheltens MD PhD4
1EIP Pharma Inc, Cambridge MA, USA, 2Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, 3Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, 4Brain Research Center, Amsterdam, NL, 5Anoixis Corporation, Framingham MA, USA

LBP33 - Impact of pre-analytical sample handling on Elecsys Aβ40, Aβ42 and tTau immunoassays in plasma
Malgorzata Rozga, PhD1, Tobias Birnner, PhD2, Richard Batrai-Utermann, MD, MBA3, Johann Karl, PhD2
1Roche Diagnostics GmbH, Penzberg, Germany, 2Genentech, A member of the Roche Group, Basel, Switzerland, 3Roche Diagnostics International AG, Rotkreuz, Switzerland

LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid Aβ1-42, Aβ1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform
Alberto Lleó12, Jordi Pegueroles2, Laia Muñoz2, Valle Camacho2, Diego López-Mora1, Alejandro Fernández-León1, Nathalie Le Bastard1, Elis Huyck1, Alicia Nada1, Verónica Olmedo1, Víctor Montal1,2, Eduard Vilaplana1,13, Rafael Blesa1,2, Juan Fortea1,2, Daniel Alcolea13
1Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Spain, 3Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Fujirebio Europe NV, Gent, Belgium, 5Fujirebio Iberia, SLU, Barcelona, Spain

LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?
Sean Stanton1, Vishnuharthi Nitta, MS2, Jessica Branning, BS2
1LifeCore Solutions, Winter Park, USA, 2ClinCloud, LLC, Orlando, USA

LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSFs measures
Nenad Bojdanovic1, Enrico Fantoni2 & Gill Farrar2
1Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, 2GE Healthcare Life Sciences, Amersham, UK and Boston, USA

LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: a pilot study
Robert J. Vassar, PhD1, Randall J. Bateman, MD2, Bruce W. Patterson, PhD2, Justyna A. Dobrowolska Zaharia, PhD1
1Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, 2Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA, 3Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

LBP38 - Reliability of a rapid APOE assay for Alzheimer’s risk assessment and clinical trial screening
Athene Lee, PhD12, William Menard, BA1, Gina Tonini, MBA1, Louisa Thompson, PhD2, Jessica Alber, PhD12, Stephen Salloway, MD12
1Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer’s disease
Steven Arnold MD, PhD1, Bianca A. Trombettad, Bechyl C. Carlby, PhD2
1Massachusetts General Hospital and Harvard Medical School, 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer’s disease
Timothy D. Boyd, PhD2, Jonathan Woodcock, MD13, Stefan Sillau, PhD13, Vanesa Adame, BS2, Thomas Borges, MD14, Ashesh Thaker, MD14, Brianne Bettscher, PhD13, Joseph Daniels, MS1, Kate Heffernan, BS1, Huntington Potter, PhD12,3
1Rocky Mountain Alzheimer’s Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Linda Cric Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 3Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 4Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 5Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA
Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function
Hiroki Umeda1, Taeko Matsumi2, Kazuki Uemura3, Hiroyuki Shimada4, Xian Wu Cheng5
1MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, 2PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, 3Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, 4Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, 5PhD, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer’s disease: Implications for dentate gyrus activity and neurogenesis
Pascal J. D. Goetghebeur1, Keith A. Wesnes2, Steven D. Targum3
1Bracket LLC, Reading, UK, 2Wesnes Cognition Ltd, Streatley on Thames, UK, 3Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil inBinswanger-Type Subcortical Vascular Dementia
Jay Cheol Kwon1, Bong Eung Kwon2, Jae Woo Kim1, Oh Jae Kwon3, Dong Goo You M.D.4, Nam-Gon Kim, M.D.5, Nach Choi M.D.6, Seon young Ahn, M.A.7, Byung Hwa Lee, M.D.8, Myong Jin Kang, M.D.9, Dae Seob Choi, M.D.10, The BKVD Study Group
1Department of Neurology, Changwon Fatima Hospital, Inje University Pusan Paik Hospital, Dong-A University Medical Center, Daegu Catholic University Medical Center, Kosin University Gospel Hospital, Gyemang Janggung Hospital, Gyongsang National University Hospital, Department of Radiology, Dong-A University Medical Center, Gyongsang National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study
Jay Cheol Kwon, MD, PhD., Kyungsoo Lee, MD, Yohan Jung, MD, PhD., Sungiae Cho, MD, PhD. And Nach-choen Choi, MD, PhD.
Changwon Fatima Hospital, Changwon, Korea, The Republic of, 2Samsung Changwon Hospital, Changwon, Korea, The Republic of, 3Gyergus Changwon National University Hospital, Chonju, Korea, The Republic of

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in the AMARANTH study
Alette M. Wessels1, Lisle R. Kingery2, Edward I. Bartolic2, Laura E. Nichelli, Jamie A. Mullen3, John R. Sims1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate, New Haven, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in Japanese ADNI study
Atsushi Iwata, MD1, Ryoko Ihara, MD2, Kazushi Suzuki, MD2, Takeshi Iwatsubo, MD2, and the Japanese ADNI1
1Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan, 2Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan

P26 - A German version of the “Five Word Test” – Discriminating patients with mild cognitive impairment/mild Alzheimer’s disease, healthy controls and patients with depression
Hausner L, MD, Dina-Biringer R, PhD, Frölich L, MD, PhD
Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment
Shim YongSoo, Jung San
Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

P53 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone, BA1, Todd M. Solomon, PhD1,2, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Coel, MSc1, & David S. Miller, MD, MA1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Bracket, Reading, UK

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer’s disease clinical trials using enhanced eCOA devices
Todd M. Solomon, PhD1,2, Jordan Mark Barbone, B.A.1, Sarah M. Karas, Psy.D1, Danielle T. DiGregorio, Psy.D1, Michael R. Maddock1, MA David M. Miller, MD1, H. Todd Feaster, Psy.D1
1Bracket, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA
P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer’s Disease Patients
Kenneth Rochwood, MD\textsuperscript{2}, Lisa McGarrigle, PhD\textsuperscript{2}
\textsuperscript{1}Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, \textsuperscript{2}DGI Clinical Inc., Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study
Anazee Khan PhD\textsuperscript{2}, Danny Ulschen BA\textsuperscript{1}, Alexandrea Atkins PhD\textsuperscript{3}, Danela Balentin BA\textsuperscript{1}, Adam Vaughan PhD\textsuperscript{1}, Heather Dickerson PhD\textsuperscript{1}, Brenda L. Plassman PhD\textsuperscript{1}, Kathleen A. Welsh-Bohmer PhD\textsuperscript{1}, Rich Keefe PhD\textsuperscript{1,3}
\textsuperscript{1}NeuroCog Trials, Durham, NC, USA, \textsuperscript{2}Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, \textsuperscript{3}Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials
Selam Negash, Christopher Weber, Christopher Randolph\textsuperscript{2}
\textsuperscript{1}MedAvante-ProPhase, \textsuperscript{2}Logala University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics’
Gæstel, Y, PhD, CERDA S., MD
Memory Center, Bogotøelle Hospital, Talence, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studies
Sietse A. M. Sijbrandt, PhD\textsuperscript{2}, Mark A. Dubbelman, MSc\textsuperscript{2}, Merite Verrijp, MSc\textsuperscript{2}, Gonzalez Sánchez Benavides, PhD\textsuperscript{2}, David Facal, PhD\textsuperscript{2}, Bruno Dubois, MD, PhD\textsuperscript{2}, Wiesje M. van der Flier, PhD\textsuperscript{2}, Hanna Juhlin, PhD\textsuperscript{2}, Cristina Lojo-Seoane\textsuperscript{3}, José Luis Molinuevo, MD, PhD\textsuperscript{2}, Arturo X. Pereiro Rozas, PhD\textsuperscript{2}, Craig Ritchie, MD, PhD\textsuperscript{2}, Magdalini Tsolaki, MD, PhD\textsuperscript{8,9}, Ya-Huei Wu, PhD\textsuperscript{10}, Stelios Zygoouris, MSc\textsuperscript{8,9}, Stephane Epelbaum, MD, PhD\textsuperscript{5}, Philip Scheltens, MD, PhD\textsuperscript{1}
\textsuperscript{1}Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, \textsuperscript{2}Department of Epidemiology and Bioinformatics, VU University, VU Medical Center, Amsterdam, the Netherlands, \textsuperscript{3}BarcelonaBeta Brain Research Center, FundacioPasqual Maragall, Barcelona, Spain, \textsuperscript{4}Hôpital Pitié-Salpêtrière, IM2A, PARIS, France, \textsuperscript{5}Department of Developmental Psychology, University of Santiago de Compostela, Spain, \textsuperscript{6}Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland, \textsuperscript{7}University of Edinburgh, United Kingdom, \textsuperscript{8}1st Department of Neurology, Aristotle University of Thessaloniki, Greece, \textsuperscript{9}Greek Association of Alzheimer’s Disease and Related Disorders, Greece, \textsuperscript{10}Braco Hospital, Paris, France II NeuroIagn Aging Research, University of Heidelberg, Germany

Susan Abushakra MD\textsuperscript{1}, Bruno Vellas MD\textsuperscript{2}, Serge Gauthier MD\textsuperscript{3}, Anton Porsteinsson MD\textsuperscript{4}, Carl Sadowsky MD\textsuperscript{5}, Aidan Power MD\textsuperscript{2}, Larry Shen PhD\textsuperscript{6}, Lu Wang MS\textsuperscript{5}, Tim Lin MS\textsuperscript{5}, John Hey PhD\textsuperscript{1}, Martin Tolar MD PhD\textsuperscript{1}
\textsuperscript{1}Alzheimer, Inc, Framingham, MA, USA, \textsuperscript{2}University of Toulouse, Toulouse, France, \textsuperscript{3}McGill University, Montreal, Canada, \textsuperscript{4}University of Rochester, Rochester, New York, \textsuperscript{5}Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, \textsuperscript{6}Pharmapace, Inc., San Diego, CA

Ana Espinosa, PhD\textsuperscript{1}, Begona Hernandez-Olasagure, PhD\textsuperscript{2}, Sonia Moreno-Grau, MSc\textsuperscript{1,2}, Luca Kleineidam, MSc\textsuperscript{2,3,4}, Stefanie Heilmann, PhD\textsuperscript{2,8}, Isabel Hernández, MD, PhD\textsuperscript{2,9}, Steffen Wolfsgruber, Dipl.-Psych\textsuperscript{2,3}, Holger Wagner, MSc\textsuperscript{2}, Maite Rosende-Roca, MD, Ana Mauleón, MD, Liliana Vargas, MD, Asunción Lafuente, MD, Octavio Rodríguez-Gómez, MD, Carla Abdeldinou, MD, Silvia Gil, MD, PhD, Marta Marquié, MD, Miguel A. Santos-Santos, MD, PhD, Ángela Sanabria, PhD, Gemma Ortega, PhD, Gemma Monté, PhD, Alba Pérez, MSc, Marta Ibarria, MSc, Susana Ruiz, MSc, Johannes Kornhuber, MD, PhD, Oliver Peters, MD, PhD, Luz Frölich, MD, PhD\textsuperscript{6}, Michael Hüll, MD, PhD\textsuperscript{2}, Jens Wiltfang, MD, PhD\textsuperscript{6}, Martin Scherer, MD, PhD\textsuperscript{6}, Tobias Luch, Dipl.-Psych\textsuperscript{2}, Steffi Riedel-Heller, MD, PhD, Laura Montoreal, MSc, Pilar Cahabate, PhD, Mariola Moreno, MSc, Silvia Prechtler, MSc, Nuria Aguiler, MSc, Iztar de Rojas, MSc, Adela Orellana, PhD, Montserrat Alegret, PhD, Sergi Valero, PhD, Markus M Nöthen, MD\textsuperscript{2}, Michael Wagner, PhD\textsuperscript{2,9}, Frank Jessen, PhD\textsuperscript{2,9}, Wolfgang Maier, MD\textsuperscript{2}, Lluis Tarraga, MSc\textsuperscript{1,2}, Mercé Boada, MD, PhD, Alfredo Ramirez, MD, PhD\textsuperscript{2,4,5}
\textsuperscript{1}Research Center and Memory Clinic Fundació ACE. Instituto Carlos de Neurolucencies Aplicades, UIC-Barcelona, Spain, \textsuperscript{2}German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, \textsuperscript{3}Department of Neurodegenerative Diseases and Genetic Psychiatry, University Hospital Bonn, Bonn, Germany, \textsuperscript{4}Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, \textsuperscript{5}Institute of Human Genetics, University of Bonn, Bonn, Germany, \textsuperscript{6}Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, \textsuperscript{7}Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, \textsuperscript{8}Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, \textsuperscript{9}Department of Psychiatry, Charité University Medicine, Berlin, Germany, \textsuperscript{10}Department of Genicar Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, \textsuperscript{11}Center for Cerebral Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany, \textsuperscript{12}Department of Psychiatry and Psychotherapy, University of Cottbus-Cottbus, Germany, \textsuperscript{13}Departments of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, \textsuperscript{14}Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
PI43 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort study (LCS)

Michael T. Ropach, PhD1, John Harrison, PhD1, Joel Kramer, PsyD1, Christopher Randolphi, PhD2, Jeffrey Kaye, MD2, Bruce Albala, PhD2, Karen Ritchie, PhD3,4

1Strategic Global Research & Development, Half Moon Bay, USA, 2Meis Cognition Ltd, UK, 3Alzheimer Center VUmc, Amsterdam, Netherlands, 4Department of Neurology Memory and Aging Center, University of California at San Francisco, San Francisco, USA, 5Department of Neurology, Loyola University Medical Center, Maywood, USA, 6Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, 7Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France, 8Faculty of Medicine, University of Montpellier, Montpellier, France, 9Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

PI44 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer’s Disease

Angelita Caputo, PhD1, Ana Graf, MD1, Cristina Lopez-Lopez, PhD, MD1, Valery Risson, PhD2, Giulia Lestini, PhD3, Neva Coello, PhD3, Amy Racine, PhD3, Ines Paule, PhD3, Luyuan Qi, PhD3, Helene Karcher, PhD3

1Novaris Pharma AG, Basel, Switzerland, 2Analytica Laser, a Cerrara company, Paris, France, 3Analytica Laser, a Cerrara company, London, UK

PI46 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries

Kirsti Kinnunen PhD1, Richard Joules, PhD1, Janet Munro, MPPhill, Iain Simpson PhD1, Robin Wols, PhD1, Yves Dauvilliers, MD PhD3

1XICO Plc, London, UK, 2Imperial College London, London, London, UK, 3Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM U661, France

PI47 - Using DCTClock’s clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnestic Mild Cognitive Impairment and probable Alzheimer’s Disease

William Souillard-Mandari, Braydon Schaible1, Randall Davis PhD2, Rhoda Au PhD3, Dana Penney PhD4

1Digital Cognition Technologies, Inc., Waltham, MA, USA, 2MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, 3Boston University Schools of Medicine and Public Health, Boston, MA, USA, 4Lahey Hospital and Medical Center, Burlington, MA, USA

PI48 - Advancing Clinical and Biomarker Research in AD: The LEAD Study

Ljana G. Apostolova, MD, Paul Aisen, MD, Ani Eloyan, PhD, Anne Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Koepe, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chiadi Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Wolk, MD, Thomas Wingo, MD, Maria Cantillo, PhD, Brad Dickerson, MD, Gil Rabinovici, MD

PI49 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer’s Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores

Suzanne Hendrix, PhD1, Noel Ellison, MS1, Jessica B. Langbaum, PhD2,3, Kewei Chen, PhD3 and David A. Bennett, MD4

1Pentara Corporation, Millcreek, UT, USA, 2Arizona Alzheimer’s Consortium, Phoenix, AZ, USA, 3University of Arizona, Tucson, AZ, USA, 4Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study

Nina Coll-Padró1, Aleix Sala-Vila1, Cinta Valls-Pedret2, Mercè Serra-Mir2,23, Montserrat Cofán2,23, Irene Roth2, Tania Freitas-Simoes2, Mónica Doménech1, Lidia Vaqué-Alcazar4, David Batrés-Faz2, Sujatha Rajaram1, Joan Sabaté3, Emilio Ros2,4

1Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic and Institut d’ Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 2LIPIClinic, Endocrinology and Nutrition Service, Hospital Clinic, Barcelona, Spain, 3CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISIC III), Spain, 4Institut d’ Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer’s disease

Suzanne B. Hendrix, PhD1, Hilktta Soiminen, MD, PhD2,3, Pieter Jelle Visser, PhD3, Alina Solomon, MD, PhD2,3, Miia Kivipelo, MD, PhD2,3, Tobias Hartmann, PhD4 on behalf of the LipiDiDiet clinical study group

1Pentara Corporation, Salt Lake City, UT, USA, 2Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 3Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, 4Department of Psychiatric and Neuropsychological, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, 5Department of Neurology, Alzheimer Center, UU University Medical Center, Amsterdam, the Netherlands, 6Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden, 7Clinical Trials Unit, Department of Ceramic Medicine, Karolinska University Hospital, Huddinge, Sweden, 8Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, 9Department of Experimental Neurology, Saarland University, Homburg, Germany
LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer’s Disease Dementia: A Phase I Clinical Trial
Hee Jin Kim, MD, PhD1,2, Kyung Rae Cho, MD2,3, Hyemin Jang, MD, PhD2,3, Jung Il Lee, MD, PhD2, Seongbeom Park, MS1,2, Soo Jin Choi4, Sung Tae Kim, MD, PhD2, Seung Hwan Moon, MD, PhD2, Kyung-Han Lee, MD, PhD2, Sang Won Seo, MD, PhD2,3, Duk L. Na, MD, PhD1,2
Departments of 1Neurology, 2Neurosurgery, 3Radiology, and 4Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 3Neuroscience Center, Samsung Medical Center, Seoul, Korea, 4Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea, 5Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, 6Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects
Michael Mullan, MBBS, PhD1,2, Laila Abdullah, PhD2, Heather Langlois2, Fiona Crawford, PhD1,2, Anders Wallin, MD3, Suzanne Hendrix, PhD4, Kaj Blennow, MD, PhD5, Brian Lawlor, MBBS6, The NILVAD consortium
1Archer Pharmaceuticals, Sarasota, FL, USA, 2Roskamp Institute, Sarasota, FL, USA, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, 4Pentara Corporation, Salt Lake City, UT, USA, 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, 6Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept?
Marie McCarthy1, Crystal Gon2
1ICON PLC, Dublin, Ireland, 2Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes
Sarah Bauermeister, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
Theme 6. Cognitive assessment and clinical trials

P6 - Evaluation of titers of antibodies against peptides of subunits NRI and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies
Takahiro Ikura, MD, PhD, Yotohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia
Dong Won Yang1, Ahro Kimi Dong Woo Lee2, Hyun Jeong Han3, Jee Hyang Jeong4, Jun Hong Lee5, Jun-Young Lee6, Kee Hyung Park7, Kyung Won Park8, SangYun Kim9, Seong Hye Choi10, Young Chul Youn11
1Department of Neurology, Catholic University of Korea, Seoul, Korea, 2Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 3Department of Neurology, Myongji Hospital, Goyang, 4Department of Neurology, Ewha Womans University Hospital, Seoul, Korea, 5Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, 6Department of Neurology, Catholic University of Korea, Seoul, Korea, 7Department of Neurology, Myongji Hospital, Goyang, 8Department of Neurology, Ewha Womans University School of Medicine, Seoul, 9Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, 10Department of Neuroscience Research, Inje University Songjeong, South Korea, 11Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment
Seon Young Ryu1, Dong Sang Lee2, MD, PhD, Taeh Jun Lee3, MD, Yu Jin Jung4, MD, PhD
1Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment
Pamela Vaccia Eds1,2, Katherine Kruczek, MS1
Bioclinica Research, The Villages, FL, USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up
Ahro Kim1, Dong Won Yang1, Dong Woo Lee2, Hyun Jeong Han3, Jee Hyang Jeong4, Jun Hong Lee5, Jun-Young Lee6, Kee Hyung Park7, Kyung Won Park8, SangYun Kim9, Seong Hye Choi10, Young Chul Youn11
1Department of Neurology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, 2Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 3Department of Neurology, Myongji Hospital, Goyang, 4Department of Neurology, Ewha Womans University Hospital, Seoul, Korea, 5Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, 6Department of Neurology, Catholic University of Korea, Seoul, Korea, 7Department of Neurology, Myongji Hospital, Goyang, 8Department of Neurology, Ewha Womans University Hospital, Seoul, Korea, 9Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, 10Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, 11Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea

P34 - A multicentre, pilot study to evaluate an Augmented Reality test (ALOIDATM) for mild cognitive impairment detection
Mircea Balasa, MD, PhD1, Adrià Tort-Merino, MSc1, Ioannis Tarmanas, PhD2,3, David Barreras-Faz, PhD4,5, Rory Boyle, MSc6, Laura Rai MSc6, Rob Whelan, PhD7, Raquel Sanchez-Valle1,2, PhD, MD
1Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain, 2Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, 3Alzoea AG, Lucerne, Switzerland, 4Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, 5School of Psychology, Trinity College Dublin, Dublin, Ireland

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects
Georg Adler, Nadja Baumgart
Institute für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian models to method normative CANTAB cognition data across adulthood
Pasquale Dente1, Elizabeth Baker1, Jack Cotter1, Francesca Cormack1, Jennifer H Barnett12
1Cambridge Cognition Limited, Cambridge, UK, 2University of Cambridge, Cambridge, UK

P47 - Predicting the course of Alzheimer’s
Samuel Judd1, PhD1, Dan Li, PhD1, Wesley K Thompson, PhD1, Michael S. Rafii, MD, PhD1, Paul S. Aisen, MD1, and Michael C Donohue, PhD1
1ATRI, University of Southern California, San Diego, CA, United States, 2Department of Family Medicine and Public Health, University of California, San Diego, USA

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI
Sharon Rosenzweig-Lipson, PhD1, Richard Mohs, PhD2, Paul Maruff, PhD2, Michela Gallagher, PhD3,4 and Arnold Babher, PhD3
1Agenebio Inc., Baltimore, MD, USA, 2Cogstate Ltd, Melbourne, Victoria, Australia, 3Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Sarbone, BA1, Todd M. Solomon, PhD1, H. Todd Feaster, PsyD1, Macarena García-Valdecasas Colell, MSc1,2, David S. Miller, MD, MA1
1Brachet, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Brachet, Reading, UK
P50 - Affective variability predicts cognitive fluctuation and decline in older adults
Edward Zamrini, MD, Michael Malek-Ahmadi, PhD, Kathy O'Connor, Sharon Schofeld
Banner Sun Health Research Institute, Sun City, USA, Banner Alzheimer's Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer’s disease
Moon Ho PARK, MD, PhD, Do-Young KWON, MD, PhD
Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMT-black and white predict the white matter hyperintensity of MRI in the community based elderly?
Young Chul Youn, MD, PhD
Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairment
Elizabeth Baker PhD, Peter Annas PhD, Giovanni B. Frisoni, MD, PhD, David Barten-Faz, MD, PhD, Beatrix Bosch PhD, Jose Luis Molinuevo, MD, PhD, Mira Didic, MD, PhD, Francesca De Anna, MD, PhD, Nicola Salvadori PhD, Jens Wilfing, MD, PhD, Flavio Nobili, MD, PhD, Nicola Girmter, Psy D, Peter Schönhömeth, MD, PhD, Pieter J. Visser, MD, PhD, Paolo M. Rossini, MD, PhD, Paola Chiovenda, MA, Pierre Payoux, MD, PhD, Andrea Soricelli, MD, PhD, Marco Salvatore, PhD, Magda Tsofali, MD, PhD, Jill C. Richardson, PhD, Régis Bordet, MD, PhD, Olivier Blin, MD, PhD, Gianluigi Fortini on behalf of the PharmaCog Consortium

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer’s Coordinating Center (NACC) dataset
Ali Tafazoli, PhD, Josh Weng, PhD, Kelly Sutton, PhD, Michal Lithiewicz, MSC, Ameya Chavan, BS, Mira Krotnева, MSc, Anuraag Kansal, PhD
Evidera, Bethesda, MD, USA, Evidera, Waltham, MA, USA, Evidera, London, UK, Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM
Daniel Lawler MD, Stephen Thein PhD
Pacific Research Network Inc., San Diego, CA, USA

P70 - Strategy or symptom? semantic clustering and risk of Alzheimer’s disease
Jamie Ford, MSC, Bang Zheng, MSC, MD, Barbara Hurtado, M.A, CPSychol, Chi Udeh-Momoh, MSC, PhD, Geraint Price, MSC, D Clin Psy
Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes
Adria Tort-Merino, MSC, Jaume Olives, MSC, Maria León, MSC, Claudia Peñaloza, PhD, Natalia Valech, MSC, Petra Grönholm-Nyman, PhD, Pablo Martínez-Lage, MD, PhD, Juan Fortea, MD, PhD, José Luis Molinuevo, MD, PhD, Raquel Sánchez-Valle, MD, PhD, Matti Laine, PhD, Antoni Rodríguez-Fornells, PhD, Lorena Rami, PhD
1Alzheimer’s Disease and Other Cognitive Disorders Unit; Neurology Service; Hospital Clinic, Barcelona, Spain, 2Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, 3Department of Psychology, Åbo Akademi University, FIN-20500 Turku, Finland, 4Neurología, Fundación CTA- Alzheimer Fuentesol, Centro de Investigación y Terapias Avanzadas; San Sebastián, Guipúzcoa España, 5Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain, 6Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas Neurodegenerativas, CIBERNED; Spain, 7BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain, 8August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, 9Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain, 10Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

P75 - Flurries and flukes: recognising unrepresentative performance on cognitive tests
Geraint Price, D Clin Psy, Bowen Su, MD
Imperial College London, UK
P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning
Alexandra S. Atkins1, Anzalee Khan1,2, Daniel Ulshen3, John Harrison4,5, Brenda L. Plassman6, Kathleen A. Welsh-Bohmer7 & Richard S.E. Keefe8
1NeuroCog Trials, Durham, NC, 2Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, 3Alzheimer Center, VUMC, Amsterdam, The Netherlands, 4UPN, King’s College, London, UK, 5Duke University Bryan ADRC, Durham, NC, 6Duke University Medical Center, Durham, NC, 7Duke University Medical Center, Durham, NC

P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study
Emilia Moreira1, Psy, MPH, PhD, Sónia Martins, Psy, PhD2, Luís Filipe Azevedo, MD, PhD3, José SilvaCardoso, MD, PhD4,5, Lia Fernandes, MD, PhD6,7
1Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Portugal, 2Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, 3Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto, Portugal, 4Department of Medicine, Faculty of Medicine, University of Porto, Portugal, 5Department of Cardiology, S. João Hospital Center, Porto, Portugal, 6Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal

P89 - The effect of dizziness in patients with cognitive impairments
Seunghie Na, MD, In-Uht Song, MD, PhD
Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD3
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P152 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD3
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study
Beatriz Valles-González1 & Vicent Rosell-Clari2
1Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia, 2Basic Psychology Department. Universitat de Valencia

P154 - Prediction of APOE ε4 Burden from Cognitive Assessment
Royall DR1,4, Palmer RF2 & for the Alzheimer’s Disease Neuroimaging Initiative†
1Departments of Psychiatry, 2Medicine, Family & Community Medicine, The University of Texas Health Science Center at San Antonio and the 3South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)

P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home? Arnelle Lepere-Desplanques1, Isabelle Hauger1, Sylvain Gaulier2, Antonis Politis3, Shima Mehrabian4, Audrey Maillet1, Pierre Krolak-Salmon5
1Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR1028, CNRS UMR 5292, Lyon University, France, 2Résidence Talanssa, Talence, France, 3National and Kapodistrian University of Athens, Athens, Greece, 4Clinic of Neurology, UH “Alexandrovskia”, Medical University, Sofia, Bulgaria

P156 - Cognitive Blachouts in Mild Cognitive Impairment of the Amnestic Type and mild Alzheimer’s Dementia
Georg Adler, Agnies Marczat, Jana Binder, Katharina Gnoza
Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasability of the neuropsychological battery camcomg-ds for the detection of cognitive decline in people with down syndrome
Laura Videla1,2, Bessy Benejam3, María Carmona-Iragui3, Susana Fernández1, Isabel Barroeta1,2, Sebastián Videla1,2, Alberto Lledó1,2, Rafael Blesa1, Juan Fortea1,2
1Alzheimer Unit - Down, Donau Medical Center, Fundació Catalóna Síndrome de Down, 2Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, 3Central Biomedical Research Center (CIBERNED)

P158 - Distinct patterns of cognitive decline between early-onset Alzheimer’s disease and late-onset Alzheimer’s disease
Adrià Tort Meringo1,2, Jaume Olives, MSc1, Neus Falgás, MD1, Mireia Balasa, PhD2, Magda Castellví1, MSc1, Sergi Borrego, MD1, Beatriz Bosch, PhD3, Maria León, MSc1, Ana Salinero, MSc1, Guadalupe Fernández, RN1, Anna Antonell, PhD1, Raquel Sánchez-Valle, MD, PhD1, Lorena Rami, PhD1, Albert Lladó, MD, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain
Late Breaking Posters

LBP47 - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnestic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial
John W. DenBoer, Ph.D., SMART Brain Aging, Inc

LBP48 - Memory errors of commission rather than errors of omission discern aging and early Alzheimer’s disease
Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS
Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

LBP49 - Standard cognitive assessment in the era of biomarkers and disease-modifiers
Marina Baccardi, PsyD, PhD,2,3 Stefano Cappa, MD, PhD,3 Bruno Dubois, MD,2 Jonathan Georges,4 Matthias Kliegl, PsyD, PhD,4 Bengt Winblad, MD, PhD,4 David Salmon, PhD,2 Giovanni Frisoni, MD,2 Andrea Monsch, PsyD, PhD,4 for the Task Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders
1Euratom, Laboratoire de Neuroimaging de l’âge, University of Geneva, Geneva, Switzerland, 2IRCCS S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy, 3Dementia Research Center, Hôpital Pitié-Salpêtrière, Paris, France, 4Alzheimer Europe, 5Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland, 6Karolinska University Hospital, Stockholm, Sweden, 7Department of Neurosciences, University of California San Diego School of Medicine, United States, 8University of Basel, Basel, Switzerland

LBP50 - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study
Alette M. Wessels, PhD,2,3,4 Jordan Mark Barbone, BA,4 Danielle T. DiGregorio, PsyD,2,3,4 David S. Miller, MD, MA,4,5 Jamie A. Mullen, MD,4,5 John R. Sims, MD,4,5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Brochet, Wayne, PA, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

LBP51 - iPS model of CHRFAM7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development
Ivanna Ilnatovich1, Tapan Nayak1, Aya Ouf1, Norbert Sule2, Barbara Birhaya1, Lee Chaves1, Anthony Auerbach1
1SUNY at Buffalo, 2Roswell Park Cancer Institute

LBP52 - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways
David Berron, PhD,2,3,4 Arturo Cardenas-Blanco, PhD,2,3,4 Daniel Bitner, MD,2,3,4 Coraline D. Metzger, MD, PhD,2,3,4 AnniD Spottke, MD,2,3,4 Michael Heneka, MD,2,3,4 Klaus Fließbach, MD,2,3,4 Anja Schneider, MD,2,3,4 Stefan J. Teipel, PhD, MD,2,3,4,5 Michael Wagner, PhD, MD,2,3,4,5 Oliver Specht, Prof. Dr.,2,3,4,5 Frank Jessen, MD, Prof.,2,3,4,5 Emn Düzel, MD, MD, and the DELCODE study group
1Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden, 2University Hospital Magdeburg, Magdeburg, Germany, 3German Center for Neurodegenerative Diseases, Magdeburg, Germany, 4German Center for Neurodegenerative Diseases (DZNE) Magdeburg, Germany, 5Institute of Cognitive Neurology, and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, 6Department of Neurology, University Hospital of Bonn, Bonn, Germany, 7Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 8DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany, 9Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, 10Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, 11German Center for Neurodegenerative Diseases, Rostock, Germany, 12Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, 13Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany, 14Department of Psychiatry, University Hospital Cologne, Cologne, Germany

P159 - High level of plasmatic amyloid Aβ 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up
Audrey Gablel1, MD, Ph.D2,3, Laure-Anne Gutiérrez1, MS2,3, Thibault Mura M.D, Ph.D2,3, Jean-François Dartigues1, Ph.D4,5, Olivier Rouaud, MD5, Jean-Charles Lambert Ph.D, MD2,3, Catherine Heimer, Ph.D4,5, Claudine Bent M.D, Ph.D4,5
1Memory Research and Resources Center, Montpellier University Hospital, Montpellier, 2Inserm U1061, La Colombière Hospital, Montpellier, 3University of Montpellier, MUIS University, Montpellier, 4Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France, 5CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France, 6CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France, 7CHRU de Lille, Lille, France, 8INSERM U744, Lille, France, 9Institut Pasteur de Lille, Lille, France, 10Université de Lille Nord de France, Lille, France

P162 - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects
William R. Shankle1, MS, MD2,3,4, Junkho Hara, PhD1,3,4 Jason R. Boch, MA,4 Dennis Fortier, MBA1, Tushar Mangrola, MS1, Michael Lee, PhD2,4, Gregory E. Alexander, PhD2,4, William H. Batchelder, PhD2,4, Ronald C. Petersen, MD, PhD4,5, Walter Kremers, PhD4,5
1Medical Care Corporation, Newport Beach, CA, USA, 2Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, 4Mayo Clinic, Rochester, MN, USA, 5University of California at Los Angeles, Los Angeles, CA, USA
Theme 7. Behavioral disorders and clinical trials

**P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer’s disease - Study of changes in cerebral blood flow by spect imaging**

Kiyoshi Kanaya1, Shine Abe2

1MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, 2MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

**P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)**

Timofey L. Galankin, MD, PhD1, Anton Y. Bespalov, MD, PhD1, Hans J. Moebius, MD, PhD1

1EXCIVA, Am, Germany, 2Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

**P43 - The effect of dizziness in patients with cognitive impairments**

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Korea, Incheon, Korea

**P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)**

Jihye Hwang, MD, PhD1, Geon-Ha Kim, MD, PhD1, Hae-Ri Na, MD, PhD1, Soo-Jin Cho, MD, PhD1, Kyung-Ho Yu, MD, PhD1, Do Hoon Kim, MD, PhD1, Jae-Hong Lee, MD, PhD1, Seong-Hye Choi, MD, PhD1

1Department of Neurology, Keimyung University School of Medicine, 2Department of Neurology, Ewha Womans University School of Medicine, 3Department of Neurology, Bobath Memorial Hospital, 4Hallym University School of Medicine, 5University of Ulsan College of Medicine, Department of Neurology, 6Inha University School of Medicine

Late Breaking Posters

**LBP53 - Prevalence of obstructive sleep apnea in Alzheimer’s disease patients**

Anna Carnes, PhD1, Carme Jorge1, MD, Benitez ID2, Faride Dahterzada1, Olga Minguez1, Raquel Huerto1, Montse Pujol1, MD, PhD, Anna Gaeta, MD2, Alfonso Arias1, MD, Aurora Gibert1, Manuel Sanchez de la Torres1, MD, PhD, Ferran Barbé2,3, MD, PhD, Gerard Piñol-Ripoll1, MD, PhD2

1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida (Spain), 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, 3IRBLleida, Lleida, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
P17 - Effect of physical activity on the progression of Alzheimer’s disease: the CREDOS study
Seong Hye Choi1, Jee Hyang Jeong2, Eun-Joo Kim3, Kyung Won Park4, Bora Yoon5, Soo Jin Yoon6, Yang-Ki Minn7, Young Ju Suh8
1Department of Neurology, Inha University School of Medicine, Incheon, South Korea, 2Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, 4Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea, 5Department of Neurology, College of Medicine, Konkuk University, Daejeon, South Korea, 6Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, 7Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, 8Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients
Kee Hyung Park, MD, PhD1, Chan-Nyoung Lee, MD, PhD2, Hojin Choi, MD, PhD3
1Department of Neurology, Gachon University, Gil Medical Center, Incheon, Korea, 2Department of Neurology, Korea University College of Medicine, Seoul, Korea, 3Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ
Adeline Rollin-Sillaire, MD1,2, Brigitte Leprince3, Catherine Adnet-Bonte, MD3, Laetitia Breuilh, PhD2, Florence Pasquier, MD, PhD2
1Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, 2Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille, 3Meotis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies
Marissa D. Zwan, PhD1, Derek Flenniken2,3, Shannon Finley, MA2, Aaron Ulbricht2,3, Rachel Nosheny, PhD2,3, Wiesje M. van der Flier, PhD1, Philip Scheitens, MD, PhD1, Diana Truran-Sacrey4, Michael W. Weiner, MD2,4, Niels D. Prins, MD, PhD1
1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, 2Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, USA, 3UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA
Theme 9. Epidemiology and clinical trials

**P17 - Awareness of Alzheimer’s dementia as their own disease in Asian Countries**
San Jung, Yong Soo Shim, Sang Yoon Kim
Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Seoul, Korea, Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

**P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoahe Integrated Care Study (TOICS)**
Hajime Tabei, MD, PhD, Ahtira Tsuzuki, RPT, DMSc2, Komachi Matsumoto, Ms3, Hiroyuki Nishiyama, Mr4, Masatoshi Ogawa, Mr4, Yoshikiyo Kanada, RPT, DMSc2
1Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan, 2Department of community care, Toyoahe city municipal office, Aichi, Japan, 3Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan

**P46 - Alzheimer’s disease drug development pipeline: 2018**
Jeffrey Cummings, MD, ScD, Garam Lee, PharmD, Aaron Ritter, MD, Kate Zhong, MD2
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 2Global Alzheimer Platform, Washington, D.C., USA

**P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer’s Dementia (EPAD): network and cluster analyses**
Lucy E Stirland, MBChB, MRCPsych, Tom C Russ MBChB, PhD, MRCPsych, Graciela Muniz Terrera, PhD, Craig W Ritchie MBChB, PhD, MRCPsych
1Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK, 2Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

**P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer’s Disease**
Samantha C Burnham, PhD, Preciosa M Coloma, MD, PhD, Teresa J Christainson, BS, Jean-François Dartigues, MD, PhD10, Rachelle Doody, MD, PhD2,3,12, Maria Vassilakoi, MD, MPH, PhD6, Barbara Schauble13 and Mary Sano, Ph.D14,15
1Department of Neurology, Mayo Clinic, Rochester, MN, USA, 2Department of Neurology, University of California Davis, Sacramento, CA, USA, 3Department of Neurology, University of California Davis, Davis, CA, USA

**P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults**
Oriol Grau-Rivera1, Juan Domingo Gispert2,3, Grégory Operto2, Carles Falcón2, Raffaele Cacciaglia1,2, Gonzalo Sánchez-Benavides2, Anna Bugulat1, Nina Gramunt3, Gemma Salvadó4, Marc Suárez-Calvet5, Carolina Minguillón,6 Karine Fauria,7 José Luis Molinuevo1,8,9,10
1BarcelonaPinea Brain Research Center, Catalonia, Spain, 2Centre de Investigació Biomèdica en Red de Bioenginyeria, Biomaterials and Nanomedicine (CIBER-BBN), Zaragoza, Spain, 3CIBER Frailty and Healthy Ageing (CIBERFES), Madrid, Spain, 4Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

**P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults**
John Olchney, MD1, Charlie DeCarli, MD1, Joshua W Miller, PhD2, David Johnson, PhD3, Sarah Tomaszewski-Farias, PhD3, Bruce Hammoch, PhD3, Britanny Dugger, PhD3, Lee-Way Jin, MD, PhD4, Mary McPhail-Ciufo, DO5, Robert Soohoo, BS5, Dan Mungas, PhD5, Danielle Harvey, PhD5
1Neurology Department, University of California Davis, Sacramento, CA, USA, 2Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, 3Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, 4Pathology Department, University of California Davis, Sacramento, CA, USA, 5Psychology Department, University of California Davis, Davis, CA, USA, 6Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

**LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer’s Disease Study and UK Biobank**
Sarah Bauermeister, PhD and John Gallagher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer's disease
Anna Carnes, PhD¹, Benitez ID², Faride Dakterzada³, Olga Minguez³, Raquel Huerto³, Montse Pujol⁴, MD, PhD, Anna Gaeta, MD², Alfonso Arias¹, MD, Aurora Gibert¹, Manuel Sanchez de la Torres¹, MD, PhD, Ferran Barbé², MD, PhD, Gerard Piñol-Ripoll², MD, PhD
¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer’s disease: a cohort study in a Health Region of Catalonia between 2002 and 2015
Carnes A¹, Torres-Bondia, FI¹, de Batlle J², Piñol-Ripoll, G¹
¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
Theme 10. Animal model and clinical trials

**P102 -** Concussive head injury exacerbates Alzheimer’s disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma1*, José V Lafuente2, Dafin F Muresanu3, Rudy J Castellani4, Mark A Smith5, Ala Nozari6, Ranjana Patnaik7, Z Ryan Tian8, Asya Ozhizilcik9, Stephen D Skaper10, Herbert Mössler11, Aruna Sharma1

1International Experimental CNS Injury & Repair (IECNIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 4University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 6Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 7School of Biomedical Engineering, Dept. of Biomaterials, Banaras Hindu University, Varanasi, India, 8Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA, 9Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 10Ever NeuroPharma, Oberburgau, Austria

**P103 -** Sleep deprivation aggravates Alzheimer’s disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma1*, José V Lafuente1, Dafin F Muresanu2, Rudy J Castellani3, Mark A Smith4, Ala Nozari5, Ranjana Patnaik6, Z Ryan Tian7, Asya Ozkizilcik6, Herbert Mössler8, Hari S Sharma9

1International Experimental CNS Injury & Repair (IECNIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 2Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 3Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 4University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 6Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 7School of Biomedical Engineering, Dept. of Biomaterials, Banaras Hindu University, Varanasi, India, 8Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA, 9Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 10Ever NeuroPharma, Oberburgau, Austria

**P104 -** The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD
Genentech, Inc, South San Francisco, CA, US

**Late Breaking Posters**

**LBP58 -** Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer’s Disease models

Fernando Gonji, PhD, Krystal Herline, PhD, Mitchell Marta-Ariza, MSc, Frances Prelli, MSc and Thomas Wisniewski, MD

1New York University School of Medicine, New York, USA
P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type
Gavrilova S.1, Volpina O.1, Kolytkhalov I.2, Ponomareva E.2, Selezevna N.3, Fedorova Y. B., Karaev D.4, A. V. Kamynin
1Mental Health Research Center, Moscow, Russia, 2Institute of bioorganic chemistry M.M. Shemyakin and Y.A. Ovchinnikov Russian Academy of Sciences, Moscow, Russia

P11 - 11β-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses-a systematic review
Sarah Gregory1, John W. Keltelby2, Tamara Miller3, Vincent S Ruffles4, Craig W. Ritchie1
1University of Edinburgh, Edinburgh, UK, 2Actigen Medical Ltd, Sydney, New South Wales, Australia

P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer’s disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimer’s Disease
Ramakrishna Nirogi, PhD1, Jyothsna Ravula, MS1, Satish Jetha, MS1, Koteswara Mudigonda, PhD2, Vinod Kumar Goyal, MS2, Santosh Kumar Pandey, MS1, Gopinadh Bhyrapuneni, PhD2, Renny Abraham, PhD1, Vijay Benade, MS1, Pradeep Jayarajan, PhD2, Anil Shinde, PhD1, John Ieni, PhD1 and Venkat Jasti, MS1
1Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

P23 - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer’s dementia: T2 PROTECT AD phase 2 study design
Irfan A. Qureshi, M.D.1, Karen Messer, Ph.D.2, Kirsten Erickson, Ph.D.2, Robert M. Berman, M.D.1, Carolyn Revta2, Tilman Oltersdorf, M.D.2, Brankot Huisa, M.D.2, Diane Jacobs, Ph.D.2, David Salmon, Ph.D.2, Doug Galasko, M.D.2, Thomas O. Obisesan, M.D.3, Neelum Aggarwal, M.D.4, Jacobo Mintzer, M.D.1, Judith Heidebrink, M.D.4, Amanda Smith, M.D.4, Miranda N. Reed, Ph.D.4, Holly C. Hunsberger, Ph.D.4, Lisa Donahue1, Kimberly Gentile1, David A. Stock, Ph.D.1, Vladimir Conic, M.D.1, Howard Feldman, M.D.1
1Biohaven Pharmaceuticals, Inc., New Haven, CT, USA, 2Alzheimer’s Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, 3Howard University, Washington, DC, USA, 4Rush University Medical Center, Chicago, IL, USA, 5Roper St. Francis Hospital, Charleston, SC, USA, 6University of Michigan, Ann Arbor, MI, USA, 7University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, 8Auburn University, Auburn, AL, USA

P56 - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo
Bengt Winblad1,2, Gunnar Nordwall1,2, Ping Yan1, Johan Lundqvist1,2, Johan Sandin1,2, Henrik Biverståhl1, Henrik Zetterberg2, Rebeca Klintenberg1, Mats Ferm1, John R Cirrito3, Jin-Moo Lee1
1AlzCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, 2AlzCure Foundation, Preclinical Research, Huddinge, Sweden, 3AstraZeneca R&D, CNS & Pain iMed, Södertälje, Sweden, 4Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, 5Washington University School of Medicine, Dept of Neurology, St Louis, USA, 6Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, 7Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden

P60 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer’s disease
Rajnish Kumar, PhD1, Pavel Pavlov, PhD1, Bengt Winblad, PhD1,2
1Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, 2Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice
Francois J. Roman1, PhD, Johann Meunier1, PhD, Laura Ceolin1, PhD, Jean-Marie Butterfly2, MS, Guillaume Blivet1, MS, Jacques Touchon1, MD, PhD
1Amygen, Montemplier-sur-Lez, France, 2Health Optimization Devices B.V., Maassluis, Netherlands, www.cognixtra.com, 3Montpellier, France, 4INSERM U1061 & Montpellier University, Montpellier, France

P84 - Clinical Development of AXS-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer’s Disease
Herriot Tabuteau, MD1, Amanda Jones, PharmD1, Cedric O’Gorman, MD1
1Axsome Therapeutics Inc., USA

P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer’s disease
Gerson D. Hernandez1, MD, MPH1, Naoko Kono, MPH1, Claudia M. Lopez, BS1, Ron Irwin, PhD1, Kathleen Rodgers, PhD1, Jimmy Wu, PhD1, Rosario Mollo, PhD1, Sonia Pawluczyl1, MD1, Meng Law, MD1, Wendy Mach, PhD1, Lon Schneider, MD, MS1, Roberta D. Brinton, PhD1
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, 2Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4TOMO Pharmacometrics, LLC, San Mateo, USA, 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 6Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
PO15 - SM07883, a novel DRYKIA inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease
Benoit Melchior, PhD1, Carolyn Lai1, Karen Duong-Polk1, Amanda Tijro1, Lauren Pitzer1, Joshua Stewart1, Luis Dellamary1, Scott Anderson1, Brian Hofiena1, Chiao-Wen Chen, PhD2, Charlene Baroga, PhD2, Gopi Mittapalli, PhD2, Sunil KC, PhD2, Philippe Marchand, PhD2, and Yusuf Yazici, MD1
Samumed, LLC, San Diego, USA

PO16 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease
Ewelina Kubiliowska1, Emily Daze1, Sylwia Wasial1, Dean Gilham1, Laura M. Tsujihawa1, Brodie Rahai1, Stephanie C. Stotz1, Christopher Halliday1, Ravi Jahagirdar1, Norman C. W. Wong1, Michael Sweeney2 and Jan O. Johansson2
1Resverlogix Corp, Calgary, AB, Canada, 2Resverlogix Inc, San Francisco, CA, USA

PO17 - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy
Fabrizio Piazza, PhD2,3, on behalf of The iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia4, Jacopo C. DiFrancesco2,3, Marialuisa Zedde1, Federica Angiulli5, Rosario Pascarella6, Roberto Marconi6, Francesco Perini6, Alberto Villarejo-Galende6, Mario Cirillo7, Berardino Orlando7,8, Ibara Masafumi9, Mehdi Touati10, Hagiwara Yuta10, Juan F. Vázquez-Costa10, Massimo Caulo11, Shima Asushi12, Alessia Giosis12, Riccardo Nitrini12, Massimo Muscillo12, 1The inflammatory cerebral amyloid angiopathy and Alzheimer's disease Biomarkers (iCAβ) International Network, University of Milano Bicocca, Monza, Italy, 2The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy, 3University of Milano Bicocca, Monza, Italy, 4National Research Council, Sezalone, Italy, 5Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, 6Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy, 7St. Bonifato Hospital, Vicenza, Italy, 8Hospital 12 de Octubre CIBERNED, Madrid, Spain, 9Università della Campania «Luigi Vanvitelli», Seconda Università degli Studi di Napoli, Italy, 10S.S. Filippo and Neri Hospital in Avellino, L’Aquila, Italy, 11National Cerebral and Cardiovascular Center, Osaka, Japan, 12Dana-Farber Brigham and Women’s Hospital, Boston, Massachusetts, Inserr U127, CNRS UMR 7725, Sorbonne Universités, Paris, France B & USA, 13St. Mariana University School of Medicine, Japan, 14Instituto de Investigacion Sanitaria la Fe (IS La Fe), Valencia, Spain, 15University «G. d’Annunzio», Chieti, Italy, 16Kyoto University Graduate School of Medicine, Kyoto, Japan, 17O.U. of Neurology, ASST Cremona, Italy, 18University of São Paulo School of Medicine, São Paulo, Brazil

PO80 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept
Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

Late Breaking Posters

LBP59 - Triple therapy with SUVN-502, a 5-HT6 antagonist, donepezil and memantine in moderate alzheimer’s disease: Baseline patient characteristics in phase-2a study
Alireza Atri, MD, PhD1, Jeffrey L. Cummings, MD, ScD1, John Ieni, PhD2, Venkat Jasti, MS3, Ramathrishna Nirogi, PhD4
1Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, 2Center for Brain/Mind medicine, Department of Neurobiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 3Cleveland Clinic, Las Vegas, NV, USA, 4Discovery Research, Suven Life Sciences, Hyderabad, India

LBP60 - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer’s disease: trial design and baseline characteristics of participants
W.J. Herring, MD, PhD1, P. Ceesay, PhD1, E. Snyder, PhD1, D. Bliwise, MD2, K. Budd, BS3, J. Hutzelmann, BS3, J. Stevens, BS3, D. Michelson, MD3
1Merch & Co. Inc., Kenilworth, NJ, USA, 2Evanry University School of Medicine, Amman, GA, USA

LBP61 - Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease
Guillaume J. Blivet, MS1, Laura Auboyer, PhD2, Johann Meunier, PhD2, Francois J. Roman, PhD2, Jacques Touchon, MD, PhD3
1REGEnLIFE SAS, Montpellier, France, 2Amygén SAS, Montferrier-sur-Lez, France, 3INSERM U1061, Montpellier, France, 4Neurology Department, University of Montpellier, France

LBP62 - Interest of REGEnLIFE RgN530 photobiomodulation medical device for the treatment of Alzheimer’s disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy
Audrey Gabelle, MD, PhD1,2, Thibault Mura, MD, PhD1,3, Karim Bennys, MD2, Sophie Navucet, MS2, Martine Flores, MS1, Laura Auboyer, PhD4, Guillaume J. Blivet, MS5, Jacques Touchon, MD, PhD1
1Memory Resource and Research Center of Montpellier, Department of Neurology, Montpellier University Hospital, France, 2MUSE University, INSERM U1061, Montpellier, France, 3Department of Epidemiologic and Clinical Research, La Colombière Hospital, Montpellier, France, 4REGEnLIFE SAS, Montpellier, France
CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors

abbvie  
Biogen  
Eisai  
GRIFOLS  
Araclon Biotech  
GRIFOLS  
IMS Health & Quintiles are now IQVIA  
Janssen  
Lilly  
Lundbeck  
Pfizer  
Roche
CTAD 2018

REGISTRATION

Early bird fees (until September 1)
Early bird registration (no lunches) 995€ - Early bird registration (3 lunches) 1124€

Early bird fees (after September 2)
Full registration (no lunches) 1287€ - Full registration (3 lunches) 1416€

Please note that registration to CTAD 2018 includes:
access to all conference sessions, attendee bag, one-year online subscription
to the Journal of Prevention of Alzheimer’s Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

ACCOMMODATIONS

Book your accommodation close to the Conference Venue

The Fairmont Rey Juan Carlos Hotel connected to the Conference Center is now sold out.

Our housing manager, Christophe Bascoul is dedicated to helping you find the best hotel close to the conference venue.

Contact: CTAD2018hotels@kris-events.com

Phone: +33 6 15 93 22 82
Keep in touch

BARCELONA 2018

CTAD Congress
Phone: + 33 (0)4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTADConference  CTAD Alzheimer  CTAD Conference

#CTAD2018

www.ctad-alzheimer.com